<html lang="en" class="pb-page js" data-request-id="94d6bc3f84721a93-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6bc3f84721a93-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/lCULQDhs5tV6azA94qzb-6-mQL0k0Ub_OD6gUpEvH4URIVnoqUOZmjix_216SPRWUF_NLXi26irHEgz4el8_2A=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6bc3f84721a93-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.9771799362472863"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Hematology/Oncology|Gastroenterology">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Treatments in Oncology|Gastrointestinal Tract Cancer (Gastroenterology)"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2111380","title":"Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma","category":"Research","type":"Original Article","topics":"Treatments in Oncology|Gastrointestinal Tract Cancer (Gastroenterology)","specialties":"Hematology/Oncology|Gastroenterology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2022-02-03T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Hematology/Oncology|Gastroenterology\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Treatments in Oncology|Gastrointestinal Tract Cancer (Gastroenterology)\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2111380","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Quick Take","title":"Immune Checkpoint Inhibitors in Esophageal Cancer","doi":"10.1056/NEJMdo006359","issueDate":"2022-02-03T00:00Z","age":"6Months-1990","isFree":"n","topics":"Treatments in Oncology|Gastrointestinal Tract Cancer (Gastroenterology)","viewType":"Full","specialties":"Hematology/Oncology|Gastroenterology"},{"type":"Research Summary","title":"Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma","doi":"10.1056/NEJMdo006360","issueDate":"2022-02-03T00:00Z","age":"6Months-1990","isFree":"n","topics":"Treatments in Oncology|Gastrointestinal Tract Cancer (Gastroenterology)","viewType":"Full","specialties":"Hematology/Oncology|Gastroenterology"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6bc3f84721a93-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma"><meta name="dc.Creator" content="Yuichiro Doki"><meta name="dc.Creator" content="Jaffer A. Ajani"><meta name="dc.Creator" content="Ken Kato"><meta name="dc.Creator" content="Jianming Xu"><meta name="dc.Creator" content="Lucjan Wyrwicz"><meta name="dc.Creator" content="Satoru Motoyama"><meta name="dc.Creator" content="Takashi Ogata"><meta name="dc.Creator" content="Hisato Kawakami"><meta name="dc.Creator" content="Chih-Hung Hsu"><meta name="dc.Creator" content="Antoine Adenis"><meta name="dc.Creator" content="Farid El Hajbi"><meta name="dc.Creator" content="Maria Di Bartolomeo"><meta name="dc.Creator" content="Maria I. Braghiroli"><meta name="dc.Creator" content="Eva Holtved"><meta name="dc.Creator" content="Sandra A. Ostoich"><meta name="dc.Creator" content="Hye R. Kim"><meta name="dc.Creator" content="Masaki Ueno"><meta name="dc.Creator" content="Wasat Mansoor"><meta name="dc.Creator" content="Wen-Chi Yang"><meta name="dc.Creator" content="Tianshu Liu"><meta name="dc.Creator" content="John Bridgewater"><meta name="dc.Creator" content="Tomoki Makino"><meta name="dc.Creator" content="Ioannis Xynos"><meta name="dc.Creator" content="Xuan Liu"><meta name="dc.Creator" content="Ming Lei"><meta name="dc.Creator" content="Kaoru Kondo"><meta name="dc.Creator" content="Apurva Patel"><meta name="dc.Creator" content="Joseph Gricar"><meta name="dc.Creator" content="Ian Chau"><meta name="dc.Creator" content="Yuko Kitagawa"><meta name="dc.Description" content="First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previo..."><meta name="Description" content="First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previo..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2022-02-03"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2111380"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202202033860508"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="YXQYoa2111380"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright Â© 2022 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2111380">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2111380">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2111380">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma | NEJM">
        <meta property="og:title" content="Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2111380">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/8c19b16a-fc05-4e40-beb9-732de1ccb47c/nejmoa2111380_f0.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/8c19b16a-fc05-4e40-beb9-732de1ccb47c/nejmoa2111380_f0.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in
poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit
over chemotherapy in previo...">
        <meta name="twitter:description" content="First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in
poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit
over chemotherapy in previo...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3416">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2111380">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2111380">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;issue:issue:doi\:10.1056/nejm_2022.386.issue-5;article:article:doi\:10.1056/NEJMoa2111380;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2111380" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2111380" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2111380" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2111380" class="inputDoi"><input type="hidden" value="Y. Doki and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2022;386:449-462" class="inputCitation"><input type="hidden" value="02-02-2022" class="inputEPubDate"><input type="hidden" value="February 2022" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6bc3f84721a93-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Yuichiro</span> <span property="familyName">Doki</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jaffer A.</span> <span property="familyName">Ajani</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-9946-0629" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-9946-0629</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ken</span> <span property="familyName">Kato</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jianming</span> <span property="familyName">Xu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Lucjan</span> <span property="familyName">Wyrwicz</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Satoru</span> <span property="familyName">Motoyama</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Takashi</span> <span property="familyName">Ogata</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+23</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Hisato</span> <span property="familyName">Kawakami</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Chih-Hung</span> <span property="familyName">Hsu</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Antoine</span> <span property="familyName">Adenis</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Farid</span> <span property="familyName">El Hajbi</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Maria</span> <span property="familyName">Di Bartolomeo</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Maria I.</span> <span property="familyName">Braghiroli</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Eva</span> <span property="familyName">Holtved</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sandra A.</span> <span property="familyName">Ostoich</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Hye R.</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Masaki</span> <span property="familyName">Ueno</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Wasat</span> <span property="familyName">Mansoor</span>, <span property="honorificSuffix">M.R.C.P., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Wen-Chi</span> <span property="familyName">Yang</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Tianshu</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">John</span> <span property="familyName">Bridgewater</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Tomoki</span> <span property="familyName">Makino</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ioannis</span> <span property="familyName">Xynos</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Xuan</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ming</span> <span property="familyName">Lei</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kaoru</span> <span property="familyName">Kondo</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Apurva</span> <span property="familyName">Patel</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Joseph</span> <span property="familyName">Gricar</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ian</span> <span property="familyName">Chau</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0286-8703" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-0286-8703</a></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Yuko</span> <span property="familyName">Kitagawa</span>, <span property="honorificSuffix">M.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the CheckMate 648 Trial Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-23</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">February 2, 2022</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2022<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">386</span></span>:<span property="pageStart">449</span>-<span property="pageEnd">462</span></div><div class="doi">DOI: 10.1056/NEJMoa2111380</div><div class="core-enumeration"><a href="/toc/nejm/386/5"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">386</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">5</span></span></a></div><div><a href="#tab-information">Copyright Â© 2022</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DYuichiro%2BDoki%252C%2BJaffer%2BA.%2BAjani%252C%2BKen%2BKato%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D386%26issueNum%3D5%26contentID%3D10.1056%252FNEJMoa2111380%26title%3DNivolumab%2BCombination%2BTherapy%2Bin%2BAdvanced%2BEsophageal%2BSquamous-Cell%2BCarcinoma%26publicationDate%3D02%252F03%252F2022" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2111380" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DYuichiro%2BDoki%252C%2BJaffer%2BA.%2BAjani%252C%2BKen%2BKato%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D386%26issueNum%3D5%26contentID%3D10.1056%252FNEJMoa2111380%26title%3DNivolumab%2BCombination%2BTherapy%2Bin%2BAdvanced%2BEsophageal%2BSquamous-Cell%2BCarcinoma%26publicationDate%3D02%252F03%252F2022" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/410f6a5d-083f-44ac-9fe7-398474eee7c9/nejmoa2111380.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2111380.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2111380" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2111380" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2111380.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previously treated patients with advanced esophageal squamous-cell carcinoma.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In this open-label, phase 3 trial, we randomly assigned adults with previously untreated, unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma in a 1:1:1 ratio to receive nivolumab plus chemotherapy, nivolumab plus the monoclonal antibody ipilimumab, or chemotherapy. The primary end points were overall survival and progression-free survival, as determined by blinded independent central review. Hierarchical testing was performed first in patients with tumor-cell programmed death ligand 1 (PD-L1) expression of 1% or greater and then in the overall population (all randomly assigned patients).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><!-- There is no content. --><nav><a href="#f0" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2111380_f0.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f0" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2111380_f0.jpg"><img src="/cms/10.1056/NEJMoa2111380/asset/8c19b16a-fc05-4e40-beb9-732de1ccb47c/assets/images/large/nejmoa2111380_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 970 patients underwent randomization. At a 13-month minimum follow-up, overall survival was significantly longer with nivolumab plus chemotherapy than with chemotherapy alone, both among patients with tumor-cell PD-L1 expression of 1% or greater (median, 15.4 vs. 9.1 months; hazard ratio, 0.54; 99.5% confidence interval [CI], 0.37 to 0.80; P&lt;0.001) and in the overall population (median, 13.2 vs. 10.7 months; hazard ratio, 0.74; 99.1% CI, 0.58 to 0.96; P=0.002). Overall survival was also significantly longer with nivolumab plus ipilimumab than with chemotherapy among patients with tumor-cell PD-L1 expression of 1% or greater (median, 13.7 vs. 9.1 months; hazard ratio, 0.64; 98.6% CI, 0.46 to 0.90; P=0.001) and in the overall population (median, 12.7 vs. 10.7 months; hazard ratio, 0.78; 98.2% CI, 0.62 to 0.98; P=0.01). Among patients with tumor-cell PD-L1 expression of 1% or greater, a significant progression-free survival benefit was also seen with nivolumab plus chemotherapy over chemotherapy alone (hazard ratio for disease progression or death, 0.65; 98.5% CI, 0.46 to 0.92; P=0.002) but not with nivolumab plus ipilimumab as compared with chemotherapy. The incidence of treatment-related adverse events of grade 3 or 4 was 47% with nivolumab plus chemotherapy, 32% with nivolumab plus ipilimumab, and 36% with chemotherapy alone.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Both first-line treatment with nivolumab plus chemotherapy and first-line treatment with nivolumab plus ipilimumab resulted in significantly longer overall survival than chemotherapy alone in patients with advanced esophageal squamous-cell carcinoma, with no new safety signals identified. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 648 ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03143153" target="_blank">NCT03143153</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo006359/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/93363cd3-4d2d-4391-8a86-fa1112428621/media/NEJMdo006359_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo006359/full/" class="ng-do-media_item-title-link">Immune Checkpoint Inhibitors in Esophageal Cancer</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 20s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Esophageal cancer causes more than half a million cancer-related deaths worldwide each year,<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1" href-manipulated="true" aria-label="Reference 1">1</a></sup> with squamous-cell carcinoma accounting for approximately 85% of cases.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2" href-manipulated="true" aria-label="Reference 2">2</a></sup> Many esophageal cancers are unresectable at diagnosis, and most patients treated with curative intent eventually have a relapse.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4 r5 r6" id="body-ref-r6" href-manipulated="true">3-6</a></sup></div><div role="paragraph">Standard fluoropyrimidine-plus-platinumâbased chemotherapy for advanced or metastatic esophageal squamous-cell carcinoma often results in poor survival outcomes (median survival, &lt;1 year).<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8 r9" id="body-ref-r9-1" href-manipulated="true">7-9</a></sup> Although chemotherapy has been a widely used first-line treatment for decades,<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r11 r12 r13" id="body-ref-r13" href-manipulated="true">10-13</a></sup> clinical benefit was recently reported with programmed death 1 (PD-1) inhibitors in combination with chemotherapy over chemotherapy alone.<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14 r15" id="body-ref-r15-1" href-manipulated="true">14,15</a></sup></div><div role="paragraph">Tumor-cell programmed death ligand 1 (PD-L1) expression in esophageal squamous-cell carcinoma is enriched,<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16" href-manipulated="true" aria-label="Reference 16">16</a></sup> with expression of 1% or greater detected in approximately 50% of patients with advanced disease.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17-1" href-manipulated="true" aria-label="Reference 17">17</a></sup> Treatment with the antiâPD-1 monoclonal antibody nivolumab has been reported to result in significantly longer overall survival than chemotherapy in previously treated patients with advanced esophageal squamous-cell carcinoma and is approved for this indication, irrespective of PD-L1 expression status.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12 r17" id="body-ref-r17-2" href-manipulated="true">12,17</a></sup> In a phase 3 trial involving patients with gastric, gastroesophageal junction, or esophageal adenocarcinoma, first-line treatment with nivolumab plus chemotherapy resulted in a significant overall survival and progression-free survival benefit as compared with chemotherapy alone, as well as in durable objective responses and an acceptable safety profile.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18" href-manipulated="true" aria-label="Reference 18">18</a></sup> First-line dual checkpoint inhibition with nivolumab and ipilimumab, an antiâcytotoxic T-lymphocyte antigen 4 antibody, has also been shown to lead to longer overall survival than chemotherapy or nivolumab monotherapy in multiple solid tumors.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19 r20 r21" id="body-ref-r21-1" href-manipulated="true">19-21</a></sup></div><div role="paragraph">CheckMate 648 is a global phase 3 trial that evaluated the efficacy and safety of both an immune checkpoint inhibitor in combination with chemotherapy and a dual immune checkpoint inhibitor combination in previously untreated patients with advanced esophageal squamous-cell carcinoma. We report the results for nivolumab plus chemotherapy and for nivolumab plus ipilimumab as compared with chemotherapy alone.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Patients</h3><div role="paragraph">Eligible patients were at least 18 years of age; had unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma, regardless of PD-L1 expression status; had disease that was not amenable to curative treatments; and had not received previous systemic therapy for advanced disease. Patients had histologically confirmed esophageal squamous-cell or adenosquamous-cell carcinoma and had measurable disease, according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Additional details are provided in the <a href="#ap2">Supplementary Appendix</a>, available with the full text of this article at NEJM.org.</div></section><section id="sec-1-2"><h3>Trial Design and Interventions</h3><div role="paragraph">CheckMate 648 is a global, randomized, open-label, phase 3 trial. Patients were randomly assigned in a 1:1:1 ratio to receive nivolumab (administered intravenously at a dose of 240 mg every 2 weeks) plus chemotherapy (consisting of a 4-week cycle of intravenous fluorouracil at a dose of 800 mg per square meter of body-surface area on days 1 through 5 and intravenous cisplatin at a dose of 80 mg per square meter on day 1); nivolumab (administered intravenously at a dose of 3 mg per kilogram of body weight every 2 weeks) plus ipilimumab (administered intravenously at a dose of 1 mg per kilogram every 6 weeks); or chemotherapy alone. Treatment continued until disease progression, unacceptable toxic effects, withdrawal of consent, or the end of the trial. Patients could receive nivolumab or nivolumab plus ipilimumab for a maximum of 2 years. Chemotherapy was administered according to the criteria and dosing schedule specified in the <a href="#ap1">protocol</a>, available at NEJM.org. Additional details are provided in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-1-3"><h3>Trial Oversight</h3><div role="paragraph">The trial was conducted in accordance with the Good Clinical Practice guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and the principles of the Declaration of Helsinki. The protocol was approved by the institutional review board or independent ethics committee at each site. All the patients provided written informed consent. An independent data monitoring committee provided oversight of safety and efficacy data.</div><div role="paragraph">Bristol Myers Squibb (the sponsor), in collaboration with Ono Pharmaceutical, funded the trial, provided the trial drugs, and collaborated with the academic authors on the trial design and on the collection, analysis, and interpretation of the data. All the authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol. The authors had access to the trial data, participated in the development or review of the manuscript, and provided final approval to submit the manuscript for publication. Medical writing support, including development of the first draft of the manuscript under the guidance of the authors, was funded by the sponsor. The authors and their institutions were required to maintain data confidentiality during the trial.</div></section><section id="sec-1-4"><h3>End Points and Assessments</h3><div role="paragraph">The primary end points were overall survival and progression-free survival, as determined by blinded independent central review on the basis of RECIST, version 1.1. The secondary end points included the percentage of patients with an objective response, which was also assessed by blinded independent central review on the basis of RECIST, version 1.1. According to the hierarchical testing procedure, the end points were assessed first in patients with tumor-cell PD-L1 expression of 1% or greater and then in the overall population (i.e., all randomly assigned patients in the trial). Key prespecified exploratory end points were the duration of response (as assessed by blinded independent central review), overall survival in subgroups defined according to tumor-cell PD-L1 expression and PD-L1 combined positive score, patient-reported outcomes, and safety. PD-L1 combined positive score was defined as the number of PD-L1âexpressing tumor cells, lymphocytes, and macrophages divided by the total number of viable tumor cells and multiplied by 100.</div><div role="paragraph">Adverse events were assessed in all the patients who had received at least one dose of the assigned treatment throughout the treatment and follow-up periods; these events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Patient-reported outcomes were evaluated with the use of the Functional Assessment of Cancer TherapyâEsophageal (FACT-E) questionnaire, which includes the item, âI am bothered by side effects of treatmentâ (single GP5 item). The threshold for clinically meaningful change for the FACT-E total score was 9.5 points.<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22 r23" id="body-ref-r23" href-manipulated="true">22,23</a></sup> Additional details are provided in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">The final analysis of progression-free survival was planned to be performed after 136 events had occurred among patients with tumor-cell PD-L1 expression of 1% or greater who had received chemotherapy alone or after a 12-month minimum follow-up, with a formal interim analysis of overall survival planned to be performed at the same time. Details regarding significance levels and sample-size considerations are described in the <a href="#ap2">Supplementary Appendix</a>.</div><div role="paragraph">For the analyses of overall survival and progression-free survival, the stratified two-sided log-rank test was used to compare the treatment groups,<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24 r25" id="body-ref-r25" href-manipulated="true">24,25</a></sup> and hazard ratios were estimated with the use of a stratified Cox proportional-hazards regression model.<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26" href-manipulated="true" aria-label="Reference 26">26</a></sup> The median overall survival and progression-free survival were estimated with the use of the KaplanâMeier method,<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27" id="body-ref-r27" href-manipulated="true" aria-label="Reference 27">27</a></sup> and the corresponding confidence intervals were calculated with the use of the logâlog transformation method. The percentages of patients with an objective response, and the corresponding two-sided 95% confidence intervals, were calculated with the use of the ClopperâPearson method,<sup><a href="#core-r28" role="doc-biblioref" data-xml-rid="r28" id="body-ref-r28" href-manipulated="true" aria-label="Reference 28">28</a></sup> and the estimates of these differences between the treatment groups were calculated with the use of the CochranâMantelâHaenszel test, with adjustment for stratification factors.<sup><a href="#core-r29" role="doc-biblioref" data-xml-rid="r29" id="body-ref-r29" href-manipulated="true" aria-label="Reference 29">29</a></sup></div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients</h3><div role="paragraph">From June 2017 through November 2019, a total of 1358 patients at 182 sites in 26 countries were assessed for eligibility. Of these patients, 970 were randomly assigned to receive nivolumab plus chemotherapy (321 patients), nivolumab plus ipilimumab (325 patients), or chemotherapy alone (324 patients) (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>). Demographic and baseline clinical characteristics were balanced across the treatment groups in the overall population (<a href="#t1">Table 1</a>) and in patients with tumor-cell PD-L1 expression of 1% or greater (Table S1). Most of the patients (680 of 970 [70%]) were from Asian countries, and 473 (49%) had tumor-cell PD-L1 expression of 1% or greater (<a href="#t1">Table 1</a>). The primary reason for treatment discontinuation was disease progression (in 184 of 310 patients [59%] who received nivolumab plus chemotherapy, in 174 of 322 patients [54%] who received nivolumab plus ipilimumab, and in 193 of 304 patients [63%] who received chemotherapy alone) (Fig. S1).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2111380_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2111380_t1.jpg"><img src="/cms/10.1056/NEJMoa2111380/asset/5f5b6e27-8e6d-4783-a75e-6f86aef64adc/assets/images/large/nejmoa2111380_t1.jpg" height="2433" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Nivolumab plus Chemotherapy<br>(N=321)</th><th class="txxx-borders">Nivolumab plus Ipilimumab<br>(N=325)</th><th class="txxr-borders">Chemotherapy (N=324)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age (range) â yr</td><td class="xxxx-borders shading">64 (40â90)</td><td class="xxxx-borders shading">63 (28â81)</td><td class="xxxr-borders shading">64 (26â81)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex â no. (%)</td><td class="xxxx-borders">253 (79)</td><td class="xxxx-borders">269 (83)</td><td class="xxxr-borders">275 (85)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race â no. (%)<a href="#t1fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Asian</td><td class="xxxx-borders">227 (71)</td><td class="xxxx-borders">231 (71)</td><td class="xxxr-borders">227 (70)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">White</td><td class="xxxx-borders shading">85 (26)</td><td class="xxxx-borders shading">79 (24)</td><td class="xxxr-borders shading">84 (26)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Black</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxx-borders">4 (1)</td><td class="xxxr-borders">6 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">8 (2)</td><td class="xxxx-borders shading">11 (3)</td><td class="xxxr-borders shading">7 (2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Geographic region â no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Asia</td><td class="xxxx-borders shading">225 (70)</td><td class="xxxx-borders shading">229 (70)</td><td class="xxxr-borders shading">226 (70)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Region other than Asia</td><td class="xxxx-borders">96 (30)</td><td class="xxxx-borders">96 (30)</td><td class="xxxr-borders">98 (30)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">ECOG performance-status score â no. (%)<a href="#t1fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">0</td><td class="xxxx-borders">150 (47)</td><td class="xxxx-borders">151 (46)</td><td class="xxxr-borders">154 (48)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">171 (53)</td><td class="xxxx-borders shading">174 (54)</td><td class="xxxr-borders shading">170 (52)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Histologic type at initial diagnosis, squamous-cell carcinoma â no. (%)<a href="#t1fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">311 (97)</td><td class="xxxx-borders">322 (&gt;99)</td><td class="xxxr-borders">318 (98)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Tumor-cell PD-L1 expression â no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">&lt;1% or indeterminate<a href="#t1fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders">163 (51)</td><td class="xxxx-borders">167 (51)</td><td class="xxxr-borders">167 (52)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">â¥1%</td><td class="xxxx-borders shading">158 (49)</td><td class="xxxx-borders shading">158 (49)</td><td class="xxxr-borders shading">157 (48)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Disease status at trial entry â no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Metastatic</td><td class="xxxx-borders shading">184 (57)</td><td class="xxxx-borders shading">196 (60)</td><td class="xxxr-borders shading">187 (58)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Recurrent, locoregional</td><td class="xxxx-borders">21 (7)</td><td class="xxxx-borders">25 (8)</td><td class="xxxr-borders">25 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Recurrent, distant</td><td class="xxxx-borders shading">72 (22)</td><td class="xxxx-borders shading">73 (22)</td><td class="xxxr-borders shading">60 (19)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Unresectable advanced</td><td class="xxxx-borders">44 (14)</td><td class="xxxx-borders">31 (10)</td><td class="xxxr-borders">52 (16)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Number of organs with metastases â no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">â¤1</td><td class="xxxx-borders">158 (49)</td><td class="xxxx-borders">160 (49)</td><td class="xxxr-borders">158 (49)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">â¥2</td><td class="xxxx-borders shading">163 (51)</td><td class="xxxx-borders shading">165 (51)</td><td class="xxxr-borders shading">166 (51)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Smoking status â no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Current or former smoker</td><td class="xxxx-borders shading">254 (79)</td><td class="xxxx-borders shading">268 (82)</td><td class="xxxr-borders shading">256 (79)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Never smoked</td><td class="xbxx-borders">67 (21)</td><td class="xbxx-borders">57 (18)</td><td class="xbxr-borders">68 (21)</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Overall Population at Baseline.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">The overall population includes all the patients who underwent randomization. Randomization was stratified according to tumor-cell programmed death ligand 1 (PD-L1) expression status (â¥1% vs. &lt;1% or indeterminate), geographic region (East Asia [Japan, Korea, and Taiwan] vs. rest of Asia vs. rest of world), Eastern Cooperative Oncology Group (ECOG) performance-status score (0 vs. 1), and number of organs with metastases (â¤1 vs. â¥2). Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t1fn2" role="paragraph">Race was reported by the patients.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t1fn3" role="paragraph">ECOG performance-status scores range from 0 to 5, with higher scores indicating greater disability.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="t1fn4" role="paragraph">A total of 9 patients who received nivolumab plus chemotherapy, 3 patients who received nivolumab plus ipilimumab, and 6 patients who received chemotherapy alone had adenosquamous-cell carcinoma of the esophagus. One patient who had been assigned to receive nivolumab plus chemotherapy had sarcomatoid carcinoma of the esophagus and underwent randomization but was not treated.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="t1fn5" role="paragraph">Three patients who received nivolumab plus ipilimumab and 2 patients who received chemotherapy alone had indeterminate tumor-cell PD-L1 expression at baseline.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Efficacy</h3><section id="sec-2-2-1"><h4>Nivolumab plus Chemotherapy as Compared with Chemotherapy Alone</h4><div role="paragraph"><a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><a id="exam-tint-one-c"></a><a id="exam-tint-one-d"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">After a minimum follow-up period of 13 months, overall survival was significantly longer with nivolumab plus chemotherapy than with chemotherapy alone among patients with tumor-cell PD-L1 expression of 1% or greater; the median overall survival was 15.4 months (95% confidence interval [CI], 11.9 to 19.5) and 9.1 months (95% CI, 7.7 to 10.0), respectively, with a 46% lower risk of death with nivolumab plus chemotherapy than with chemotherapy alone (hazard ratio, 0.54; 99.5% CI, 0.37 to 0.80; P&lt;0.001) (<a href="#f1">Figure 1A</a>). The percentage of patients who were alive at 12 months was 58% and 37%, respectively. Similarly, nivolumab plus chemotherapy resulted in significantly longer overall survival than chemotherapy alone in the overall population; the median overall survival was 13.2 months (95% CI, 11.1 to 15.7) and 10.7 months (95% CI, 9.4 to 11.9), respectively, with a 26% lower risk of death with nivolumab plus chemotherapy than with chemotherapy alone (hazard ratio, 0.74; 99.1% CI, 0.58 to 0.96; P=0.002)</span> (<a href="#f1">Figure 1B</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2111380_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2111380_f1.jpg"><img src="/cms/10.1056/NEJMoa2111380/asset/b46d9399-dbd4-4138-97a7-d8827026288e/assets/images/large/nejmoa2111380_f1.jpg" height="3438" width="2259" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Overall Survival and Progression-free Survival with Nivolumab plus Chemotherapy as Compared with Chemotherapy Alone.</div><div class="notes"><div role="doc-footnote">Shown are KaplanâMeier estimates of overall survival in patients with tumor-cell programmed death ligand 1 (PD-L1) expression of 1% or greater (Panel A) and in the overall population (Panel B) and KaplanâMeier estimates of progression-free survival (as assessed by blinded independent central review) in patients with tumor-cell PD-L1 expression of 1% or greater (Panel C) and in the overall population (Panel D). The P value for the analysis of progression-free survival in the overall population did not meet the prespecified boundary for significance. Symbols indicate censored data.</div></div></figcaption></figure></div><div role="paragraph"><a id="exam-tint-two-c"></a><a id="exam-tint-two-d"></a><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="two-c two-d">Progression-free survival, as determined by blinded independent central review, was significantly longer with nivolumab plus chemotherapy than with chemotherapy alone among patients with tumor-cell PD-L1 expression of 1% or greater; the median progression-free survival was 6.9 months (95% CI, 5.7 to 8.3) and 4.4 months (95% CI, 2.9 to 5.8), respectively (hazard ratio for disease progression or death, 0.65; 98.5% CI, 0.46 to 0.92; P=0.002) (<a href="#f1">Figure 1C</a>). In the overall population, the difference in progression-free survival between the group that received nivolumab plus chemotherapy and the group that received chemotherapy alone did not meet the prespecified boundary for significance of 0.015; the median progression-free survival was 5.8 months (95% CI, 5.6 to 7.0) and 5.6 months (95% CI, 4.3 to 5.9), respectively (hazard ratio, 0.81; 98.5% CI, 0.64 to 1.04; P=0.04)</span> (<a href="#f1">Figure 1D</a>).</div><div role="paragraph">The percentage of patients who had an objective response, as determined by blinded independent central review, was higher with nivolumab plus chemotherapy than with chemotherapy alone among patients with tumor-cell PD-L1 expression of 1% or greater (53% vs. 20%), as well as in the overall population (47% vs. 27%), and the median duration of response was longer (8.4 vs. 5.7 months and 8.2 vs. 7.1 months, respectively). The percentage of patients who received nivolumab plus chemotherapy and had a complete response was more than triple the percentage of patients who received chemotherapy alone and had a complete response (16% vs. 5%) for patients with tumor-cell PD-L1 expression of 1% or greater and more than double (13% vs. 6%) for the overall population (<a href="#t2">Table 2</a> and Fig. S2A and S2B).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2111380_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2111380_t2.jpg"><img src="/cms/10.1056/NEJMoa2111380/asset/245eea64-8dca-4dd9-bbf7-e3912fd97720/assets/images/large/nejmoa2111380_t2.jpg" height="1210" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders" colspan="3"><span>Patients with Tumor-Cell PD-L1 Expression of â¥1%</span></th><th class="txxr-borders" colspan="3"><span>Overall Population</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Nivolumab plus Chemotherapy<br>(N=158)</th><th class="xxxx-borders">Nivolumab plus Ipilimumab<br>(N=158)</th><th class="xxxx-borders">Chemotherapy<br>(N=157)</th><th class="xxxx-borders">Nivolumab plus Chemotherapy<br>(N=321)</th><th class="xxxx-borders">Nivolumab plus Ipilimumab<br>(N=325)</th><th class="xxxr-borders">Chemotherapy<br>(N=324)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Objective response rate</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients (%)</td><td class="xxxx-borders">84 (53)</td><td class="xxxx-borders">56 (35)</td><td class="xxxx-borders">31 (20)</td><td class="xxxx-borders">152 (47)</td><td class="xxxx-borders">90 (28)</td><td class="xxxr-borders">87 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">95% CI</td><td class="xxxx-borders shading">45â61</td><td class="xxxx-borders shading">28â43</td><td class="xxxx-borders shading">14â27</td><td class="xxxx-borders shading">42â53</td><td class="xxxx-borders shading">23â33</td><td class="xxxr-borders shading">22â32</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Best overall response â no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Complete response</td><td class="xxxx-borders shading">26 (16)</td><td class="xxxx-borders shading">28 (18)</td><td class="xxxx-borders shading">8 (5)</td><td class="xxxx-borders shading">43 (13)</td><td class="xxxx-borders shading">36 (11)</td><td class="xxxr-borders shading">20 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Partial response</td><td class="xxxx-borders">58 (37)</td><td class="xxxx-borders">28 (18)</td><td class="xxxx-borders">23 (15)</td><td class="xxxx-borders">109 (34)</td><td class="xxxx-borders">54 (17)</td><td class="xxxr-borders">67 (21)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Stable disease</td><td class="xxxx-borders shading">40 (25)</td><td class="xxxx-borders shading">43 (27)</td><td class="xxxx-borders shading">72 (46)</td><td class="xxxx-borders shading">103 (32)</td><td class="xxxx-borders shading">103 (32)</td><td class="xxxr-borders shading">148 (46)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Progressive disease</td><td class="xxxx-borders">22 (14)</td><td class="xxxx-borders">48 (30)</td><td class="xxxx-borders">24 (15)</td><td class="xxxx-borders">42 (13)</td><td class="xxxx-borders">103 (32)</td><td class="xxxr-borders">38 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Could not be evaluated</td><td class="xxxx-borders shading">12 (8)</td><td class="xxxx-borders shading">11 (7)</td><td class="xxxx-borders shading">30 (19)</td><td class="xxxx-borders shading">24 (7)</td><td class="xxxx-borders shading">29 (9)</td><td class="xxxr-borders shading">51 (16)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median time to response (range) â mo<a href="#t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders">1.5 (0.6â4.3)</td><td class="xxxx-borders">1.5 (1.2â8.4)</td><td class="xxxx-borders">1.5 (1.3â9.7)</td><td class="xxxx-borders">1.5 (0.6â6.8)</td><td class="xxxx-borders">1.5 (1.2â8.4)</td><td class="xxxr-borders">1.5 (1.1â9.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median duration of response (95% CI) â mo<a href="#t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">8.4 (6.9â12.4)</td><td class="xxxx-borders shading">11.8 (7.1â27.4)</td><td class="xxxx-borders shading">5.7 (4.4â8.7)</td><td class="xxxx-borders shading">8.2 (6.9â9.7)</td><td class="xxxx-borders shading">11.1 (8.3â14.0)</td><td class="xxxr-borders shading">7.1 (5.7â8.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Patients with ongoing response â no. (%)<a href="#t2fn2" role="doc-noteref">â </a></td><td class="xbxx-borders">11 (13)</td><td class="xbxx-borders">14 (25)</td><td class="xbxx-borders">1 (3)</td><td class="xbxx-borders">26 (17)</td><td class="xbxx-borders">20 (22)</td><td class="xbxr-borders">5 (6)</td></tr></tbody></table></div><figcaption><div class="caption">Antitumor Activity, as Assessed by Blinded Independent Central Review.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Included are all patients who underwent randomization and had target-lesion measurements at baseline, as assessed by blinded independent central review. Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t2fn2" role="paragraph">This analysis included only patients who had an objective response.</div></div></div></figcaption></figure></div></section><section id="sec-2-2-2"><h4>Nivolumab plus Ipilimumab as Compared with Chemotherapy</h4><div role="paragraph"><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">Overall survival was significantly longer with nivolumab plus ipilimumab than with chemotherapy among patients with tumor-cell PD-L1 expression of 1% or greater; the median overall survival was 13.7 months (95% CI, 11.2 to 17.0) and 9.1 months (95% CI, 7.7 to 10.0), respectively, with a 36% lower risk of death with nivolumab plus ipilimumab than with chemotherapy (hazard ratio, 0.64; 98.6% CI, 0.46 to 0.90; P=0.001). The percentage of patients who were alive at 12 months was 57% and 37%, respectively (<a href="#f2">Figure 2A</a>). Treatment with nivolumab plus ipilimumab also resulted in significantly longer overall survival than chemotherapy in the overall population; the median overall survival was 12.7 months (95% CI, 11.3 to 15.5) and 10.7 months (95% CI, 9.4 to 11.9), respectively, with a 22% lower risk of death with nivolumab plus ipilimumab than with chemotherapy (hazard ratio, 0.78; 98.2% CI, 0.62 to 0.98; P=0.01) (<a href="#f2">Figure 2B</a>).</span></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2111380_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2111380_f2.jpg"><img src="/cms/10.1056/NEJMoa2111380/asset/2295f8d9-17e1-43cd-b70c-08421da6ab1e/assets/images/large/nejmoa2111380_f2.jpg" height="3438" width="2259" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Overall Survival and Progression-free Survival with Nivolumab plus Ipilimumab as Compared with Chemotherapy.</div><div class="notes"><div role="doc-footnote">Shown are KaplanâMeier estimates of overall survival in patients with tumor-cell PD-L1 expression of 1% or greater (Panel A) and in the overall population (Panel B) and KaplanâMeier estimates of progression-free survival (as assessed by blinded independent central review) in patients with tumor-cell PD-L1 expression of 1% or greater (Panel C) and in the overall population (Panel D). Symbols indicate censored data.</div></div></figcaption></figure></div><div role="paragraph"><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="two-c two-d">Among patients with tumor-cell PD-L1 expression of 1% or greater, the median progression-free survival, according to blinded independent central review, was 4.0 months (95% CI, 2.4 to 4.9) with nivolumab plus ipilimumab and 4.4 months (95% CI, 2.9 to 5.8) with chemotherapy, and the difference between the groups did not meet the criteria for statistical significance (hazard ratio for disease progression or death, 1.02; 98.5% CI, 0.73 to 1.43; P=0.90) (<a href="#f2">Figure 2C</a>). Therefore, progression-free survival was not tested in the overall population (<a href="#f2">Figure 2D</a>).</span></div><div role="paragraph">Among patients with tumor-cell PD-L1 expression of 1% or greater, the percentage who had an objective response, as assessed by blinded independent central review, was higher with nivolumab plus ipilimumab than with chemotherapy (35% vs. 20%), and the percentage of patients who received nivolumab plus ipilimumab and had a complete response was more than three times as high as the percentage who received chemotherapy and had a complete response (18% vs. 5%). The median duration of response was 11.8 months with nivolumab plus ipilimumab and 5.7 months with chemotherapy (<a href="#t2">Table 2</a> and Fig. S2C). In the overall population, the percentage of patients who had an objective response was similar in the two groups (28% and 27%, respectively), and the percentage of patients who had a complete response with nivolumab plus ipilimumab was nearly twice as high as the percentage with chemotherapy (11% vs. 6%). The median duration of response in the overall population was 11.1 months and 7.1 months, respectively (<a href="#t2">Table 2</a> and Fig. S2D).</div></section><section id="sec-2-2-3"><h4>Subgroup Analyses</h4><div role="paragraph">Overall survival favored nivolumab plus chemotherapy or nivolumab plus ipilimumab over chemotherapy alone across multiple prespecified subgroups in both the overall population and in patients with tumor-cell PD-L1 expression of 1% or greater, including the subgroups defined according to geographic region, Eastern Cooperative Oncology Group performance-status score, and the number of organs with metastases (Fig. S3A through S3D). Hazard ratios were consistently below 1 in all the tumor-cell PD-L1 expression subgroups (1%, 5%, and 10% cutoffs), with the highest magnitude of benefit observed in the subgroup of patients with tumor-cell PD-L1 expression of 1% or greater (Fig. S3B and S3D). Among patients with tumor-cell PD-L1 expression of less than 1%, the median overall survival was approximately 12 months in each treatment group, and no progression-free survival benefit was observed with the nivolumab-containing regimens as compared with chemotherapy alone (Table S2). However, the percentage of patients who had tumor-cell PD-L1 expression of less than 1% and had an objective response was higher with nivolumab plus chemotherapy than with chemotherapy alone (42% vs. 34%), and the percentage of patients who had a duration of response of at least 12 months was higher with both nivolumab-containing regimens than with chemotherapy alone (38% for nivolumab plus chemotherapy, 47% for nivolumab plus ipilimumab, and 27% for chemotherapy alone) (Table S2). Among the patients with a PD-L1 combined positive score of 1 or higher (824 of 906 [91%]), the median overall survival was 13.8 months (hazard ratio for death, 0.69; 95% CI, 0.56 to 0.84) with nivolumab plus chemotherapy and 12.7 months (hazard ratio, 0.76; 95% CI, 0.62 to 0.93) with nivolumab plus ipilimumab as compared with 9.8 months with chemotherapy alone (Fig. S3B and S3D). Among the few patients with a PD-L1 combined positive score of less than 1 (82 of 906 [9%]), the median overall survival was 9.9 months (hazard ratio, 0.98; 95% CI, 0.50 to 1.95) with nivolumab plus chemotherapy and 11.5 months (hazard ratio, 1.00; 95% CI, 0.52 to 1.94) with nivolumab plus ipilimumab as compared with 12.1 months with chemotherapy alone.</div></section></section><section id="sec-2-3"><h3>Exposure and Safety</h3><div role="paragraph">The median duration of treatment was 5.7 months with nivolumab plus chemotherapy, 2.8 months with nivolumab plus ipilimumab, and 3.4 months with chemotherapy alone (Table S3). Treatment-related adverse events are summarized in <a href="#t3">Table 3</a>. <a id="exam-tint-three-a"></a><a id="exam-tint-three-b"></a><a id="exam-tint-three-c"></a><a id="exam-tint-three-d"></a><span id="tint5" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-b three-c three-d">The incidence of treatment-related adverse events of grade 3 or 4 was higher among patients who received nivolumab plus chemotherapy (147 patients [47%]) than among those who received nivolumab plus ipilimumab (102 patients [32%]) or chemotherapy alone (108 patients [36%]).</span> Treatment-related serious adverse events of any grade were more common with nivolumab plus chemotherapy (74 patients [24%]) and nivolumab plus ipilimumab (103 patients [32%]) than with chemotherapy alone (49 patients [16%]). The percentage of patients who had a treatment-related adverse event of any grade that led to discontinuation of any drug in the regimen was higher with nivolumab plus chemotherapy (106 patients [34%]) than with nivolumab plus ipilimumab or chemotherapy alone (57 patients [18%] and 59 patients [19%], respectively). The incidence of treatment-related deaths was similar across the groups: 5 patients (2%) with nivolumab plus chemotherapy, 8 (2%) with nivolumab plus ipilimumab, and 6 (2%) with chemotherapy alone. These included three deaths in the group that received nivolumab plus ipilimumab and two deaths in the group that received chemotherapy that were attributed to disease, other reasons, or an unknown cause for which fatal treatment-related serious adverse events were also reported by the investigator. Most of the treatment-related adverse events with potential immunologic causes were grade 1 or 2; events of grade 3 or 4 occurred in no more than 6% of the patients across the treatment groups and organ categories (Table S4). Data regarding subsequent therapies are provided in Table S5.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2111380_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2111380_t3.jpg"><img src="/cms/10.1056/NEJMoa2111380/asset/cd6bd818-93fa-4c56-aa39-b6344b20dea4/assets/images/large/nejmoa2111380_t3.jpg" height="2578" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="2"><span>Nivolumab plus<br>Chemotherapy<br>(N=310)</span></th><th class="txxx-borders" colspan="2"><span>Nivolumab plus<br>Ipilimumab<br>(N=322)</span></th><th class="txxr-borders" colspan="2"><span>Chemotherapy<br>(N=304)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 3 or 4</th><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 3 or 4</th><th class="xxxx-borders">Any Grade</th><th class="xxxr-borders">Grade 3 or 4</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="6"><span>number of patients with event (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any treatment-related adverse event</td><td class="xxxx-borders shading">297 (96)</td><td class="xxxx-borders shading">147 (47)</td><td class="xxxx-borders shading">256 (80)</td><td class="xxxx-borders shading">102 (32)</td><td class="xxxx-borders shading">275 (90)</td><td class="xxxr-borders shading">108 (36)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Treatment-related serious adverse event</td><td class="xxxx-borders">74 (24)</td><td class="xxxx-borders">57 (18)</td><td class="xxxx-borders">103 (32)</td><td class="xxxx-borders">73 (23)</td><td class="xxxx-borders">49 (16)</td><td class="xxxr-borders">38 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Treatment-related adverse event leading to trial-drug discontinuation<a href="#t3fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">106 (34)</td><td class="xxxx-borders shading">29 (9)</td><td class="xxxx-borders shading">57 (18)</td><td class="xxxx-borders shading">41 (13)</td><td class="xxxx-borders shading">59 (19)</td><td class="xxxr-borders shading">14 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Treatment-related adverse event leading to death<a href="#t3fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">5 (2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">8 (2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">6 (2)</td><td class="xxxr-borders">â</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Treatment-related adverse events reported in â¥10% of patients in any group</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nausea</td><td class="xxxx-borders">182 (59)</td><td class="xxxx-borders">11 (4)</td><td class="xxxx-borders">26 (8)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxx-borders">158 (52)</td><td class="xxxr-borders">8 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders shading">132 (43)</td><td class="xxxx-borders shading">13 (4)</td><td class="xxxx-borders shading">19 (6)</td><td class="xxxx-borders shading">5 (2)</td><td class="xxxx-borders shading">130 (43)</td><td class="xxxr-borders shading">9 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Stomatitis</td><td class="xxxx-borders">98 (32)</td><td class="xxxx-borders">20 (6)</td><td class="xxxx-borders">14 (4)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">71 (23)</td><td class="xxxr-borders">5 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Anemia</td><td class="xxxx-borders shading">93 (30)</td><td class="xxxx-borders shading">30 (10)</td><td class="xxxx-borders shading">12 (4)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">67 (22)</td><td class="xxxr-borders shading">17 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Decreased neutrophil count</td><td class="xxxx-borders">65 (21)</td><td class="xxxx-borders">25 (8)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">52 (17)</td><td class="xxxr-borders">24 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Fatigue</td><td class="xxxx-borders shading">61 (20)</td><td class="xxxx-borders shading">7 (2)</td><td class="xxxx-borders shading">29 (9)</td><td class="xxxx-borders shading">4 (1)</td><td class="xxxx-borders shading">50 (16)</td><td class="xxxr-borders shading">11 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">60 (19)</td><td class="xxxx-borders">3 (1)</td><td class="xxxx-borders">32 (10)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">46 (15)</td><td class="xxxr-borders">6 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">59 (19)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">7 (2)</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxx-borders shading">66 (22)</td><td class="xxxr-borders shading">1 (&lt;1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Vomiting</td><td class="xxxx-borders">56 (18)</td><td class="xxxx-borders">7 (2)</td><td class="xxxx-borders">18 (6)</td><td class="xxxx-borders">4 (1)</td><td class="xxxx-borders">49 (16)</td><td class="xxxr-borders">9 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Malaise</td><td class="xxxx-borders shading">50 (16)</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxx-borders shading">12 (4)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">45 (15)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Decreased white-cell count</td><td class="xxxx-borders">43 (14)</td><td class="xxxx-borders">11 (4)</td><td class="xxxx-borders">3 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">28 (9)</td><td class="xxxr-borders">6 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hiccups</td><td class="xxxx-borders shading">42 (14)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">53 (17)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Increased blood creatinine level</td><td class="xxxx-borders">39 (13)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxx-borders">5 (2)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">32 (11)</td><td class="xxxr-borders">1 (&lt;1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Decreased platelet count</td><td class="xxxx-borders shading">36 (12)</td><td class="xxxx-borders shading">3 (1)</td><td class="xxxx-borders shading">6 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">32 (11)</td><td class="xxxr-borders shading">5 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mucosal inflammation</td><td class="xxxx-borders">33 (11)</td><td class="xxxx-borders">8 (3)</td><td class="xxxx-borders">4 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">26 (9)</td><td class="xxxr-borders">4 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Alopecia</td><td class="xxxx-borders shading">31 (10)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">32 (11)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Rash</td><td class="xxxx-borders">24 (8)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxx-borders">55 (17)</td><td class="xxxx-borders">7 (2)</td><td class="xxxx-borders">5 (2)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pruritus</td><td class="xxxx-borders shading">23 (7)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">43 (13)</td><td class="xxxx-borders shading">3 (1)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Hypothyroidism</td><td class="xbxx-borders">18 (6)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">43 (13)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxr-borders">0</td></tr></tbody></table></div><figcaption><div class="caption">Treatment-Related Adverse Events in All the Patients Who Received Trial Treatment.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Included are all the patients who received at least one dose of the assigned treatment. All events were reported between the first dose of treatment and 30 days after the last dose of treatment. Any relation between treatment and adverse events reported in the patients who received nivolumab plus chemotherapy was attributed to either nivolumab or any of the chemotherapies or both. Any relation between treatment and adverse events reported in the patients who received nivolumab plus ipilimumab was attributed to either nivolumab or ipilimumab or both. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0, and the <i>Medical Dictionary for Regulatory Activities</i>, version 23.1.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t3fn2" role="paragraph">This category refers to adverse events leading to discontinuation of any drug in the regimen.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t3fn3" role="paragraph">Treatment-related adverse events leading to death were reported regardless of time frame. Treatment-related deaths in the group that received nivolumab plus chemotherapy were from acute kidney injury, pneumonia, pneumonitis, pneumonitis or respiratory-tract infection, and pneumatosis intestinalis (in 1 patient each). Treatment-related deaths in the group that received nivolumab plus ipilimumab were from pneumonitis (in 2 patients) and acute respiratory distress syndrome, interstitial lung disease, and pulmonary embolism (in 1 patient each). In addition, three deaths in the group that received nivolumab plus ipilimumab (one from other reasons and two from disease) were also reported by the investigator as treatment-related serious adverse events that eventually had a fatal outcome (acute kidney injury, general physical health deterioration, and internal hemorrhage). Treatment-related deaths in the group that received chemotherapy alone were from acute kidney injury, pneumonia, sepsis, and septic shock (in 1 patient each). Two additional deaths in the chemotherapy group (one from other reasons and one from an unknown cause) were also reported by the investigator as treatment-related serious adverse events that eventually had a fatal outcome (acute respiratory failure and death).</div></div></div></figcaption></figure></div></section><section id="sec-2-4"><h3>Patient-Reported Outcomes</h3><div role="paragraph">A longitudinal mixed-model analysis of FACT-E scores through week 49 showed an overall increase in the least-squares mean change from baseline with nivolumab plus chemotherapy (4.98 points; 95% CI, 2.68 to 7.27), nivolumab plus ipilimumab (3.45 points; 95% CI, 0.96 to 5.94), and chemotherapy alone (1.54 points; 95% CI, â1.26 to 4.33) in the overall population. These improvements from baseline were not clinically meaningful, which indicates that health-related quality of life was maintained during the treatment period (Fig. S4A). Except at baseline, the percentage of patients who reported not being bothered by treatment side effects over time was higher with nivolumab plus ipilimumab than with chemotherapy, whereas percentages with nivolumab plus chemotherapy were similar to those with chemotherapy alone (Fig. S4B and S4C).</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In the CheckMate 648 trial, first-line treatment with nivolumab in combination with chemotherapy or as a chemotherapy-free combination with ipilimumab resulted in a significant overall survival benefit over chemotherapy alone in patients with advanced esophageal squamous-cell carcinoma. In both the overall population and among patients with tumor-cell PD-L1 expression of 1% or greater, the median overall survival exceeded 1 year, with patients surviving 2.0 to 6.3 months longer with a nivolumab-containing regimen than with chemotherapy alone. Survival at 1 year was 10 to 21 percentage points higher in the groups that received a nivolumab-containing regimen than in the group that received chemotherapy alone. An initial increased incidence of early death among the patients who received nivolumab plus ipilimumab did not preclude long-term benefit; after the KaplanâMeier curves crossed at approximately 6.5 months, they showed sustained separation favoring nivolumab plus ipilimumab. Nivolumab plus chemotherapy was also associated with significantly longer progression-free survival than chemotherapy alone among patients with tumor-cell PD-L1 expression of 1% or greater.</div><div role="paragraph"><a id="exam-tint-two-a"></a><a id="exam-tint-two-b"></a><span id="tint6" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b">Treatment with either nivolumab-based regimen resulted in a higher percentage of patients who had a complete response, as well as in more durable responses, than chemotherapy alone.</span> Among the three treatment regimens, nivolumab plus chemotherapy led to the highest percentages of patients with an objective response and nivolumab plus ipilimumab resulted in the longest median duration of response.</div><div role="paragraph">The percentages of patients who had treatment-related adverse events of grade 3 or 4 and the percentages of those who had a treatment-related adverse event of any grade that led to discontinuation of any trial drug were the highest with nivolumab plus chemotherapy and the lowest with nivolumab plus ipilimumab. Health-related quality of life was maintained over the course of the treatment period for the nivolumab-based regimens, and fewer patients who were receiving nivolumab plus ipilimumab reported being bothered by treatment side effects than did patients who were receiving a chemotherapy-based treatment.</div><div role="paragraph">PD-1 inhibitors have been associated with a survival benefit in previously treated patients with advanced esophageal squamous-cell carcinoma.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r30 r31 r32" id="body-ref-r32" href-manipulated="true">17,30â32</a></sup> In the CheckMate 648 trial, first-line treatment with nivolumab plus chemotherapy and nivolumab plus ipilimumab showed a significant overall survival benefit. Pembrolizumab plus chemotherapy and camrelizumab plus chemotherapy have also been reported to result in longer median overall survival than chemotherapy alone in this population; these findings show the benefit of adding a PD-1 inhibitor to chemotherapy.<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14 r15" id="body-ref-r15-2" href-manipulated="true">14,15</a></sup></div><div role="paragraph">In the CheckMate 648 trial, overall survival favored the nivolumab-containing regimens across most of the prespecified subgroups. Although the hazard ratios in a few subgroups were close to or exceeded 1 (e.g., female sex and locoregional recurrence), the median overall survival with chemotherapy alone was notably longer in these subgroups than the expected median of less than 12 months and the number of patients was small, both of which limited interpretation of the results.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8 r9" id="body-ref-r9-2" href-manipulated="true">7-9</a></sup> The prevalence of tumor-cell PD-L1 expression of 1% or greater in the CheckMate 648 trial was approximately 50%, which is consistent with previous reports.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r33" id="body-ref-r33" href-manipulated="true">17,33</a></sup> Hazard ratios for death were less than 1 across all the tumor-cell PD-L1 expression subgroups for both nivolumab-containing regimens. The magnitude of the overall survival benefit was greater in patients with tumor-cell PD-L1 expression of 1% or greater, with no further enrichment at higher cutoffs, than in patients with tumor-cell PD-L1 expression of less than 1%, in whom the hazard ratios were close to 1. The median overall survival with chemotherapy alone was 3 months longer in patients with tumor-cell PD-L1 expression of less than 1% than in those with tumor-cell PD-L1 expression of 1% or greater; these findings are consistent with results reported in an earlier trial involving previously treated patients with esophageal squamous-cell carcinoma.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17-5" href-manipulated="true" aria-label="Reference 17">17</a></sup> Among patients with tumor-cell PD-L1 expression of less than 1%, the percentage of patients with responses lasting at least 1 year was higher with both nivolumab-containing regimens than with chemotherapy alone, a finding that suggests that longer follow-up may result in extended overall survival.</div><div role="paragraph">The preplanned exploratory subgroup analyses of overall survival that were performed according to PD-L1 combined positive score showed the overall survival benefit of the nivolumab-containing regimens in the subgroup that had a combined positive score of 1 or higher, a subgroup that accounted for more than 90% of all the patients in the trial who had a quantifiable combined positive score. Among the patients with a PD-L1 combined positive score of less than 1, the small sample size and wide confidence intervals limited data interpretation. The PD-L1 combined positive score has been shown to be a more appropriate scoring method than tumor-cell PD-L1 expression in predicting the efficacy of immune checkpoint inhibitorâbased therapies for gastroesophageal adenocarcinoma.<sup><a href="#core-r34" role="doc-biblioref" data-xml-rid="r34 r35" id="body-ref-r35" href-manipulated="true">34,35</a></sup> In patients with esophageal squamous-cell carcinoma in the CheckMate 648 trial, the observed hazard ratios and corresponding confidence intervals for overall survival across the tumor-cell PD-L1 expression and exploratory PD-L1 combined positive score subgroups suggest that both scoring methods have clinical utility.</div><div role="paragraph">A significant progression-free survival benefit, as assessed by blinded independent central review, was observed with nivolumab plus chemotherapy over chemotherapy alone in patients with tumor-cell PD-L1 expression of 1% or greater but not in the overall population; no benefit in progression-free survival was observed in either patient population with nivolumab plus ipilimumab as compared with chemotherapy alone. A lack of progression-free survival benefit despite longer overall survival has previously been observed with immunotherapies and is probably attributable to their delayed treatment effect relative to chemotherapy.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r36 r37" id="body-ref-r37" href-manipulated="true">17,36,37</a></sup></div><div role="paragraph">The higher percentages of patients who had objective responses and complete responses and the longer durations of response that were seen with nivolumab plus chemotherapy as compared with chemotherapy alone both in patients with tumor-cell PD-L1 expression of 1% or greater and in the overall population in the CheckMate 648 trial were consistent with reports of pembrolizumab plus chemotherapy and camrelizumab plus chemotherapy in patients with esophageal cancer.<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14 r15" id="body-ref-r15-3" href-manipulated="true">14,15</a></sup> Nivolumab plus ipilimumab was also associated with notably higher percentages of patients who had a complete response than chemotherapy, both among patients with tumor-cell PD-L1 expression of 1% or greater and in the overall population, in addition to longer median durations of response (by 6 months and 4 months, respectively). However, the percentages of patients with progressive disease were also higher with nivolumab plus ipilimumab. Longer follow-up will further elucidate the magnitude of long-term clinical benefit with nivolumab plus ipilimumab.</div><div role="paragraph">The safety profiles of nivolumab plus chemotherapy and nivolumab plus ipilimumab were consistent with the known profiles of the individual components at similar doses.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r17 r19 r38" id="body-ref-r38" href-manipulated="true">9,17,19,38</a></sup> Among the patients who received nivolumab plus chemotherapy, adverse events were mainly driven by chemotherapy (with the most common events being nausea, decreased appetite, and stomatitis), with some immune-mediated events. In contrast, treatment with nivolumab plus ipilimumab primarily resulted in immune-mediated adverse events (the most common being rash, pruritus, and hypothyroidism) at frequencies expected with this combination.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21-2" href-manipulated="true" aria-label="Reference 21">21</a></sup> Although treatment-related serious adverse events were more common with the nivolumab-based regimens than with chemotherapy alone, treatment-related adverse events of grade 3 or 4 that had potential immunologic causes occurred in no more than 6% of the patients across the organ categories. The incidence of treatment-related deaths was similar across the three treatment groups and occurred in approximately 2% of the patients in each group.</div><div role="paragraph">The trial was not designed to compare outcomes between nivolumab plus chemotherapy and nivolumab plus ipilimumab or to determine which treatment should be used for specific subgroups. Multiple factors may influence the choice of regimen in clinical practice, including an individual patientâs need for a relatively rapid treatment effect and the occurrence of side effects associated with chemotherapy that a patient considers to be unacceptable. Additional exploratory post hoc analyses may help to identify demographic characteristics or baseline disease characteristics that could predict efficacy outcomes for each nivolumab-containing regimen.</div><div role="paragraph">A limitation of this trial was its open-label design. Although the primary end point of overall survival was objectively determined and therefore was not biased by the type of treatment, causality assessments of adverse events and responses to questionnaires evaluating patient-reported outcomes may have been influenced by knowledge of the assigned treatment.</div><div role="paragraph">First-line treatment of advanced esophageal squamous-cell carcinoma with either nivolumab plus chemotherapy or nivolumab plus ipilimumab resulted in a significant overall survival benefit and durable responses as compared with chemotherapy alone. The safety profiles of each treatment were consistent with the known safety profiles of the individual components in each regimen.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">Bristol Myers Squibb</span> and Ono Pharmaceutical.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the patients and their families for making this trial possible; the investigators and the clinical trial teams at Bristol Myers Squibb (Princeton, NJ) and Ono Pharmaceutical (Osaka, Japan) for CheckMate 648 trial support; Amy Lever (Bristol Myers Squibb, Princeton, NJ) for contributions as the protocol manager for this trial; Yasuhiro Matsumura (Ono Pharmaceutical) for support for the design and conduct of this trial; Steven Blum (Bristol Myers Squibb, Princeton, NJ) and Fiona Taylor (Adelphi Values, Boston, MA) for support with analysis of patient-reported outcomes; Dako (an Agilent Technologies company, Santa Clara, CA) for collaborative development of the PD-L1 IHC 28-8 pharmDx assay; and Puneet Dang and Amanda Hatton of Parexel for medical-writing assistance, funded by Bristol Myers Squibb.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap0" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Research Summary</span> <span class="core-filename">(nejmoa2111380_research-summary.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2111380/suppl_file/nejmoa2111380_research-summary.pdf" download="nejmoa2111380_research-summary.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2111380_research-summary.pdf" data-doi="10.1056/NEJMoa2111380">Download</a></li><li>1.43 MB</li></ul></div></div><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2111380_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2111380/suppl_file/nejmoa2111380_protocol.pdf" download="nejmoa2111380_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2111380_protocol.pdf" data-doi="10.1056/NEJMoa2111380">Download</a></li><li>35.87 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2111380_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2111380/suppl_file/nejmoa2111380_appendix.pdf" download="nejmoa2111380_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2111380_appendix.pdf" data-doi="10.1056/NEJMoa2111380">Download</a></li><li>1.84 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2111380_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2111380/suppl_file/nejmoa2111380_disclosures.pdf" download="nejmoa2111380_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2111380_disclosures.pdf" data-doi="10.1056/NEJMoa2111380">Download</a></li><li>1.27 MB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2111380_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2111380/suppl_file/nejmoa2111380_data-sharing.pdf" download="nejmoa2111380_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2111380_data-sharing.pdf" data-doi="10.1056/NEJMoa2111380">Download</a></li><li>71.14 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <em>CA Cancer J Clin</em> 2021;71:209-249.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3322/caac.21660" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33538338/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000614520100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+cancer+statistics+2020%3A+GLOBOCAN+estimates+of+incidence+and+mortality+worldwide+for+36+cancers+in+185+countries.&amp;publication_year=2021&amp;journal=CA+Cancer+J+Clin&amp;pages=209-249&amp;doi=10.3322%2Fcaac.21660&amp;pmid=33538338" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Arnold M, Ferlay J, van Berge Henegouwen MI, Soerjomataram I. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. <em>Gut</em> 2020;69:1564-1571.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/gutjnl-2020-321600" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32606208/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000567562200026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+burden+of+oesophageal+and+gastric+cancer+by+histology+and+subsite+in+2018.&amp;publication_year=2020&amp;journal=Gut&amp;pages=1564-1571&amp;doi=10.1136%2Fgutjnl-2020-321600&amp;pmid=32606208" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Smyth EC, Lagergren J, Fitzgerald RC, et al. Oesophageal cancer. <em>Nat Rev Dis Primers</em> 2017;3:17048-17048.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrdp.2017.48" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28748917/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000407302400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Oesophageal+cancer.&amp;publication_year=2017&amp;journal=Nat+Rev+Dis+Primers&amp;pages=17048-17048&amp;doi=10.1038%2Fnrdp.2017.48&amp;pmid=28748917" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Cancer Research UK. Oesophageal cancer incidence (<a href="https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/oesophageal-cancer#heading-Zero">https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/oesophageal-cancer#heading-Zero</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Cancer+Research+UK.+Oesophageal+cancer+incidence+%28https%3A%2F%2Fwww.cancerresearchuk.org%2Fhealth-professional%2Fcancer-statistics%2Fstatistics-by-cancer-type%2Foesophageal-cancer%23heading-Zero%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Patel N, Benipal B. Incidence of esophageal cancer in the United States from 2001â2015: a United States cancer statistics analysis of 50 states. <em>Cureus</em> 2018;10(12):e3709-e3709.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30788198/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000461069500015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Incidence+of+esophageal+cancer+in+the+United+States+from+2001%E2%80%932015%3A+a+United+States+cancer+statistics+analysis+of+50+states.&amp;publication_year=2018&amp;journal=Cureus&amp;pages=e3709-e3709&amp;pmid=30788198" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2012. <em>Esophagus</em> 2019;16:221-245.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10388-019-00674-z" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31098822/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000472853200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comprehensive+registry+of+esophageal+cancer+in+Japan%2C+2012.&amp;publication_year=2019&amp;journal=Esophagus&amp;pages=221-245&amp;doi=10.1007%2Fs10388-019-00674-z&amp;pmid=31098822" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. <em>Eur J Cancer</em> 1997;33:1216-1220.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0959-8049(97)00088-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9301445/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1997XR38300020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomised+phase+II+study+of+cisplatin+and+5-fluorouracil+%285-FU%29+versus+cisplatin+alone+in+advanced+squamous+cell+oesophageal+cancer.&amp;publication_year=1997&amp;journal=Eur+J+Cancer&amp;pages=1216-1220&amp;doi=10.1016%2FS0959-8049%2897%2900088-9&amp;pmid=9301445" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] outcomes (median survival, &lt;1 year). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] limited interpretation of the results. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Lee SJ, Kim S, Kim M, et al. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study. <em>BMC Cancer</em> 2015;15:693-693.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s12885-015-1716-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26468007/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000362705500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Capecitabine+in+combination+with+either+cisplatin+or+weekly+paclitaxel+as+a+first-line+treatment+for+metastatic+esophageal+squamous+cell+carcinoma%3A+a+randomized+phase+II+study.&amp;publication_year=2015&amp;journal=BMC+Cancer&amp;pages=693-693&amp;doi=10.1186%2Fs12885-015-1716-9&amp;pmid=26468007" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] outcomes (median survival, &lt;1 year). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] limited interpretation of the results. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Moehler M, Maderer A, Thuss-Patience PC, et al. Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). <em>Ann Oncol</em> 2020;31:228-235.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.annonc.2019.10.018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31959339/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000516712400010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cisplatin+and+5-fluorouracil+with+or+without+epidermal+growth+factor+receptor+inhibition+panitumumab+for+patients+with+non-resectable%2C+advanced+or+metastatic+oesophageal+squamous+cell+cancer%3A+a+prospective%2C+open-label%2C+randomised+phase+III+AIO%2FEORTC+trial+%28POWER%29.&amp;publication_year=2020&amp;journal=Ann+Oncol&amp;pages=228-235&amp;doi=10.1016%2Fj.annonc.2019.10.018&amp;pmid=31959339" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] outcomes (median survival, &lt;1 year). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] limited interpretation of the results. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r38" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] the individual components at similar doses. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. <em>Esophagus</em> 2019;16:1-24.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10388-018-0641-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30171413/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457767800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Esophageal+cancer+practice+guidelines+2017+edited+by+the+Japan+Esophageal+Society%3A+part+1.&amp;publication_year=2019&amp;journal=Esophagus&amp;pages=1-24&amp;doi=10.1007%2Fs10388-018-0641-9&amp;pmid=30171413" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Lordick F, Mariette C, Haustermans K, ObermannovÃ¡ R, Arnold D. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <em>Ann Oncol</em> 2016;27:Suppl 5:v50-v57.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdw329" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27664261/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000385125200004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Oesophageal+cancer%3A+ESMO+clinical+practice+guidelines+for+diagnosis%2C+treatment+and+follow-up.&amp;publication_year=2016&amp;journal=Ann+Oncol&amp;pages=v50-v57&amp;doi=10.1093%2Fannonc%2Fmdw329&amp;pmid=27664261" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Clinical practice guidelines in oncology: esophageal and esophagogastric junction cancers, version 1. Plymouth Meeting, PA: National Comprehensive Cancer Network, 2022.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Clinical+practice+guidelines+in+oncology%3A+esophageal+and+esophagogastric+junction+cancers%2C+version+1.+Plymouth+Meeting%2C+PA%3A+National+Comprehensive+Cancer+Network%2C+2022." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r13" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] used first-line treatment for decades, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] irrespective of PD-L1 expression status. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">National Health Commission of the Peopleâs Republic of China. Chinese guidelines for diagnosis and treatment of esophageal carcinoma 2018 (English version). <em>Chin J Cancer Res</em> 2019;31:223-258.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.21147/j.issn.1000-9604.2019.02.01" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31156297/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000473282800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Chinese+guidelines+for+diagnosis+and+treatment+of+esophageal+carcinoma+2018+%28English+version%29.&amp;publication_year=2019&amp;journal=Chin+J+Cancer+Res&amp;pages=223-258&amp;doi=10.21147%2Fj.issn.1000-9604.2019.02.01&amp;pmid=31156297" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Xu R, Luo H, Lu J, et al. ESCORT-1st: a randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC). <em>J Clin Oncol</em> 2021;39:Suppl 15. abstract 4000.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2021.39.15_suppl.4000" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000708120602103" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ESCORT-1st%3A+a+randomized%2C+double-blind%2C+placebo-controlled%2C+phase+3+trial+of+camrelizumab+plus+chemotherapy+versus+chemotherapy+in+patients+with+untreated+advanced+or+metastatic+esophageal+squamous+cell+carcinoma+%28ESCC%29.&amp;publication_year=2021&amp;journal=J+Clin+Oncol&amp;doi=10.1200%2FJCO.2021.39.15_suppl.4000" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with chemotherapy over chemotherapy alone. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of adding a PD-1 inhibitor to chemotherapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] in patients with esophageal cancer. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Sun J-M, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. <em>Lancet</em> 2021;398:759-771.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(21)01234-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34454674/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000689712800025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+plus+chemotherapy+versus+chemotherapy+alone+for+first-line+treatment+of+advanced+oesophageal+cancer+%28KEYNOTE-590%29%3A+a+randomised%2C+placebo-controlled%2C+phase+3+study.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=759-771&amp;doi=10.1016%2FS0140-6736%2821%2901234-4&amp;pmid=34454674" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with chemotherapy over chemotherapy alone. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of adding a PD-1 inhibitor to chemotherapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] in patients with esophageal cancer. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Salem ME, Puccini A, Xiu J, et al. Comparative molecular analyses of esophageal squamous cell carcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma. <em>Oncologist</em> 2018;23:1319-1327.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1634/theoncologist.2018-0143" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29866946/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000449946000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+molecular+analyses+of+esophageal+squamous+cell+carcinoma%2C+esophageal+adenocarcinoma%2C+and+gastric+adenocarcinoma.&amp;publication_year=2018&amp;journal=Oncologist&amp;pages=1319-1327&amp;doi=10.1634%2Ftheoncologist.2018-0143&amp;pmid=29866946" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. <em>Lancet Oncol</em> 2019;20:1506-1517.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(19)30626-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31582355/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000493897500042" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+versus+chemotherapy+in+patients+with+advanced+oesophageal+squamous+cell+carcinoma+refractory+or+intolerant+to+previous+chemotherapy+%28ATTRACTION-3%29%3A+a+multicentre%2C+randomised%2C+open-label%2C+phase+3+trial.&amp;publication_year=2019&amp;journal=Lancet+Oncol&amp;pages=1506-1517&amp;doi=10.1016%2FS1470-2045%2819%2930626-6&amp;pmid=31582355" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] 50% of patients with advanced disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] irrespective of PD-L1 expression status. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r32" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] esophageal squamous-cell carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r33" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] which is consistent with previous reports. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] with esophageal squamous-cell carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r37" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] treatment effect relative to chemotherapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r38" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] the individual components at similar doses. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. <em>Lancet</em> 2021;398:27-40.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(21)00797-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34102137/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000668969500027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-line+nivolumab+plus+chemotherapy+versus+chemotherapy+alone+for+advanced+gastric%2C+gastro-oesophageal+junction%2C+and+oesophageal+adenocarcinoma+%28CheckMate+649%29%3A+a+randomised%2C+open-label%2C+phase+3+trial.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=27-40&amp;doi=10.1016%2FS0140-6736%2821%2900797-2&amp;pmid=34102137" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced nonâsmall-cell lung cancer. <em>N Engl J Med</em> 2019;381:2020-2031.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_20_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2111380&amp;key=10.1056%2FNEJMoa1910231&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31562796/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000505218800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+plus+ipilimumab+in+advanced+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=2020-2031&amp;doi=10.1056%2FNEJMoa1910231&amp;pmid=31562796" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] monotherapy in multiple solid tumors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r38" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the individual components at similar doses. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. <em>N Engl J Med</em> 2017;377:1345-1356.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_21_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2111380&amp;key=10.1056%2FNEJMoa1709684&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28889792/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000412375000014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Overall+survival+with+combined+nivolumab+and+ipilimumab+in+advanced+melanoma.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=1345-1356&amp;doi=10.1056%2FNEJMoa1709684&amp;pmid=28889792" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <em>Lancet</em> 2021;397:375-386.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)32714-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33485464/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000614227700025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-line+nivolumab+plus+ipilimumab+in+unresectable+malignant+pleural+mesothelioma+%28CheckMate+743%29%3A+a+multicentre%2C+randomised%2C+open-label%2C+phase+3+trial.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=375-386&amp;doi=10.1016%2FS0140-6736%2820%2932714-8&amp;pmid=33485464" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] monotherapy in multiple solid tumors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] frequencies expected with this combination. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Darling G, Eton DT, Sulman J, Casson AG, Celia D. Validation of the functional assessment of cancer therapy esophageal cancer subscale. <em>Cancer</em> 2006;107:854-863.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/cncr.22055" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16826587/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000239950000024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Validation+of+the+functional+assessment+of+cancer+therapy+esophageal+cancer+subscale.&amp;publication_year=2006&amp;journal=Cancer&amp;pages=854-863&amp;doi=10.1002%2Fcncr.22055&amp;pmid=16826587" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Ringash J, OâSullivan B, Bezjak A, Redelmeier DA. Interpreting clinically significant changes in patient-reported outcomes. <em>Cancer</em> 2007;110:196-202.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/cncr.22799" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17546575/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000247384200024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interpreting+clinically+significant+changes+in+patient-reported+outcomes.&amp;publication_year=2007&amp;journal=Cancer&amp;pages=196-202&amp;doi=10.1002%2Fcncr.22799&amp;pmid=17546575" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. <em>Cancer Chemother Rep</em> 1966;50:163-170.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/5910392/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evaluation+of+survival+data+and+two+new+rank+order+statistics+arising+in+its+consideration.&amp;publication_year=1966&amp;journal=Cancer+Chemother+Rep&amp;pages=163-170&amp;pmid=5910392" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Peto R, Peto J. Asymptotically efficient rank invariant test procedures. <em>J R Stat Soc [Ser A]</em> 1972;135:185-207.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2307/2344317" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1972N166900020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Asymptotically+efficient+rank+invariant+test+procedures.&amp;publication_year=1972&amp;journal=J+R+Stat+Soc+%5BSer+A%5D&amp;pages=185-207&amp;doi=10.2307%2F2344317" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Cox DR. Regression models and life-tables. <em>J R Stat Soc [Ser B]</em> 1972;34:187-202.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.2517-6161.1972.tb00899.x" target="_blank">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Regression+models+and+life-tables.&amp;publication_year=1972&amp;journal=J+R+Stat+Soc+%5BSer+B%5D&amp;pages=187-202&amp;doi=10.1111%2Fj.2517-6161.1972.tb00899.x" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. <em>J Am Stat Assoc</em> 1958;53:457-481.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/01621459.1958.10501452" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1958WX09300012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nonparametric+estimation+from+incomplete+observations.&amp;publication_year=1958&amp;journal=J+Am+Stat+Assoc&amp;pages=457-481&amp;doi=10.1080%2F01621459.1958.10501452" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. <em>Biometrika</em> 1934;26:404-413.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/biomet/26.4.404" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000200863400002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+use+of+confidence+or+fiducial+limits+illustrated+in+the+case+of+the+binomial.&amp;publication_year=1934&amp;journal=Biometrika&amp;pages=404-413&amp;doi=10.1093%2Fbiomet%2F26.4.404" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Koch GG, Carr GJ, Amara IA, Stokes ME, Uryniak TJ. Categorical data analysis. In: Berry DA, ed. <em>Statistical methodology in the pharmaceutical sciences.</em> Boca Raton, FL: CRC Press, 1989:389-474.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Categorical+data+analysis.&amp;publication_year=1989&amp;pages=389-474" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Kojima T, Shah MA, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. <em>J Clin Oncol</em> 2020;38:4138-4148.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.20.01888" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33026938/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000598458500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized+phase+III+KEYNOTE-181+study+of+pembrolizumab+versus+chemotherapy+in+advanced+esophageal+cancer.&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;pages=4138-4148&amp;doi=10.1200%2FJCO.20.01888&amp;pmid=33026938" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigatorâs choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. <em>Lancet Oncol</em> 2020;21:832-842.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(20)30110-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32416073/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000544057400034" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Camrelizumab+versus+investigator%E2%80%99s+choice+of+chemotherapy+as+second-line+therapy+for+advanced+or+metastatic+oesophageal+squamous+cell+carcinoma+%28ESCORT%29%3A+a+multicentre%2C+randomised%2C+open-label%2C+phase+3+study.&amp;publication_year=2020&amp;journal=Lancet+Oncol&amp;pages=832-842&amp;doi=10.1016%2FS1470-2045%2820%2930110-8&amp;pmid=32416073" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. <em>Lancet Oncol</em> 2017;18:631-639.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(17)30181-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28314688/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000400401100051" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+treatment+for+oesophageal+squamous-cell+carcinoma%3A+an+open-label%2C+multicentre%2C+phase+2+trial.&amp;publication_year=2017&amp;journal=Lancet+Oncol&amp;pages=631-639&amp;doi=10.1016%2FS1470-2045%2817%2930181-X&amp;pmid=28314688" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="r33" class="citations"><div class="citation"><div class="citation-content">Kato K, Doki Y, Ura T, et al. Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. <em>Cancer Sci</em> 2020;111:1676-1684.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/cas.14380" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32160365/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000529314800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+efficacy+and+predictive+correlates+of+response+to+nivolumab+in+Japanese+patients+with+esophageal+cancer.&amp;publication_year=2020&amp;journal=Cancer+Sci&amp;pages=1676-1684&amp;doi=10.1111%2Fcas.14380&amp;pmid=32160365" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="r34" class="citations"><div class="citation"><div class="citation-content">Lei M, Siemers NO, Pandya D, et al. Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab Â± ipilimumab in gastric cancer/gastroesophageal junction cancer. <em>Clin Cancer Res</em> 2021;27:3926-3935.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-20-2790" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33782030/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000674703200017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Analyses+of+PD-L1+and+inflammatory+gene+expression+association+with+efficacy+of+nivolumab+%C2%B1+ipilimumab+in+gastric+cancer%2Fgastroesophageal+junction+cancer.&amp;publication_year=2021&amp;journal=Clin+Cancer+Res&amp;pages=3926-3935&amp;doi=10.1158%2F1078-0432.CCR-20-2790&amp;pmid=33782030" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="r35" class="citations"><div class="citation"><div class="citation-content">Kulangara K, Zhang N, Corigliano E, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. <em>Arch Pathol Lab Med</em> 2019;143:330-337.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.5858/arpa.2018-0043-OA" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30028179/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000459956200013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+utility+of+the+combined+positive+score+for+programmed+death+ligand-1+expression+and+the+approval+of+pembrolizumab+for+treatment+of+gastric+cancer.&amp;publication_year=2019&amp;journal=Arch+Pathol+Lab+Med&amp;pages=330-337&amp;doi=10.5858%2Farpa.2018-0043-OA&amp;pmid=30028179" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="r36" class="citations"><div class="citation"><div class="citation-content">Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous nonâsmall-cell lung cancer. <em>N Engl J Med</em> 2015;373:1627-1639.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r37"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_37_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2111380&amp;key=10.1056%2FNEJMoa1507643&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26412456/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000363317800008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+versus+docetaxel+in+advanced+nonsquamous+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=1627-1639&amp;doi=10.1056%2FNEJMoa1507643&amp;pmid=26412456" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="r37" class="citations"><div class="citation"><div class="citation-content">Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. <em>N Engl J Med</em> 2016;375:1856-1867.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r37"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_38_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2111380&amp;key=10.1056%2FNEJMoa1602252&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27718784/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000387534200009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+for+recurrent+squamous-cell+carcinoma+of+the+head+and+neck.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=1856-1867&amp;doi=10.1056%2FNEJMoa1602252&amp;pmid=27718784" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="r38" class="citations"><div class="citation"><div class="citation-content">Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group trial. <em>Jpn J Clin Oncol</em> 1992;22:172-176.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/1518165/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1992JL70600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+II+evaluation+of+cisplatin+and+5-fluorouracil+in+advanced+squamous+cell+carcinoma+of+the+esophagus%3A+a+Japanese+Esophageal+Oncology+Group+trial.&amp;publication_year=1992&amp;journal=Jpn+J+Clin+Oncol&amp;pages=172-176&amp;pmid=1518165" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/386/5"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">386</span></span> â¢ <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">5</span></span> â¢ <span property="datePublished">February 3, 2022</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">449</span>-<span property="pageEnd">462</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright Â© 2022 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2111380" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa2111380?sg=AbW1N">Chinese Translation ä¸­æç¿»è¯</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: February 2, 2022</div><div><b class="core-label">Published in issue</b>: February 3, 2022</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/gastrointestinal-tract-cancer-gastroenterology" alt="View article keyword Gastrointestinal Tract Cancer (Gastroenterology)" data-interactiontype="article_recirculation_click">Gastrointestinal Tract Cancer (Gastroenterology)</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/treatments-in-oncology" alt="View article keyword Treatments in Oncology" data-interactiontype="article_recirculation_click">Treatments in Oncology</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Yuichiro</span> <span property="familyName">Doki</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jaffer A.</span> <span property="familyName">Ajani</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-9946-0629" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-9946-0629</a></span>, <span property="author" typeof="Person"><span property="givenName">Ken</span> <span property="familyName">Kato</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jianming</span> <span property="familyName">Xu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Lucjan</span> <span property="familyName">Wyrwicz</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Satoru</span> <span property="familyName">Motoyama</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Takashi</span> <span property="familyName">Ogata</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Hisato</span> <span property="familyName">Kawakami</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Chih-Hung</span> <span property="familyName">Hsu</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Antoine</span> <span property="familyName">Adenis</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Farid</span> <span property="familyName">El Hajbi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Maria</span> <span property="familyName">Di Bartolomeo</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Maria I.</span> <span property="familyName">Braghiroli</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Eva</span> <span property="familyName">Holtved</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sandra A.</span> <span property="familyName">Ostoich</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Hye R.</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Masaki</span> <span property="familyName">Ueno</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Wasat</span> <span property="familyName">Mansoor</span>, <span property="honorificSuffix">M.R.C.P., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Wen-Chi</span> <span property="familyName">Yang</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Tianshu</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">John</span> <span property="familyName">Bridgewater</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Tomoki</span> <span property="familyName">Makino</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ioannis</span> <span property="familyName">Xynos</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Xuan</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ming</span> <span property="familyName">Lei</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kaoru</span> <span property="familyName">Kondo</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Apurva</span> <span property="familyName">Patel</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Joseph</span> <span property="familyName">Gricar</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ian</span> <span property="familyName">Chau</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0286-8703" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-0286-8703</a></span>, and <span property="author" typeof="Person"><span property="givenName">Yuko</span> <span property="familyName">Kitagawa</span>, <span property="honorificSuffix">M.D.</span></span>, for <span property="author" typeof="Person">the CheckMate 648 Trial Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From Osaka University Graduate School of Medicine, Osaka (Y.D., T.M.), National Cancer Center Hospital (K. Kato), Toranomon Hospital (M.U.), and Keio University School of Medicine (Y.K.), Tokyo, Akita University Hospital, Akita (S.M.), Kanagawa Cancer Center, Kanagawa (T.O.), and Kindai University Faculty of Medicine, Osakasayama (H.K.) â all in Japan; University of Texas M.D. Anderson Cancer Center, Houston (J.A.A.); Fifth Medical Center, Chinese PLA General Hospital, Beijing (J.X.), and Zhongshan Hospital, Fudan University, Shanghai (T.L.); Klinika Onkologii i Radioterapii, Narodowy Instytut Onkologii, Warsaw, Poland (L.W.); National Taiwan University Hospital, Taipei (C.-H.H.), and E-Da Hospital and I-Shou University, Kaohsiung (W.-C.Y.) â both in Taiwan; Institut de Recherche en CancÃ©rologie de Montpellier, INSERM, UniversitÃ© Montpellier, Institut du Cancer de Montpellier, Montpellier (A.A.), and Centre Oscar Lambret, Lille (F.E.H.) â both in France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (M.D.B.); Institute of Cancer of SÃ£o Paulo, University of SÃ£o Paulo, SÃ£o Paulo (M.I.B.); Odense University Hospital, Odense, Denmark (E.H.); Hospital Provincial del Centenario, Rosario, Argentina (S.A.O.); the Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea (H.R.K.); the Christie NHS Foundation Trust, Manchester (W.M.), the UCL Cancer Institute, University College London, London (J.B.), and the Royal Marsden Hospital (Surrey), Sutton (I.C.) â all in the United Kingdom; and Bristol Myers Squibb, Princeton, NJ (I.X., X.L., M.L., K. Kondo, A.P., J.G.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Dr. Kato can be contacted at <a href="mailto:kenkato@ncc.go.jp">kenkato@ncc.go.jp</a> or at the Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Chuo City, Tokyo, 104-0045, Japan.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A complete list of the sites and investigators in the CheckMate 648 trial is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div><div role="doc-footnote"><div id="fn2" role="paragraph">Drs. Doki and Ajani contributed equally to this article.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">704</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2111380" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="fcd86fa9-897e-0805-830d-bc5f6c2ab133"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121999997" style="display:inline-block;">
                <img alt="Article has an altmetric score of 379" src="https://badges.altmetric.com/?size=320&amp;score=379&amp;types=mbvcttwf" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121999997">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_fcd86fa9-897e-0805-830d-bc5f6c2ab133" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121999997&amp;tab=news">
          Picked up by <b>39</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121999997&amp;tab=blogs">
          Blogged by <b>3</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121999997&amp;tab=twitter">
          Posted by <b>128</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121999997&amp;tab=facebook">
          On <b>2</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121999997&amp;tab=wikipedia">
          Referenced in <b>1</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #94DB5E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121999997&amp;tab=video">
          On <b>2</b> videos
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121999997&amp;tab=guidelines">
          Referenced in <b>2</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>412</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6bc3f84721a93-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2111380"> <input type="hidden" name="downloadFileName" value="csp_386_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.386.issue-5%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2111380%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="704" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Alessandro Caputo, </li><li class="list-inline-item cited-by__entry__author">Valentina Angerilli, </li><li class="list-inline-item cited-by__entry__author">Alessandro Gambella, </li><li class="list-inline-item cited-by__entry__author">Vincenzo LâImperio, </li><li class="list-inline-item cited-by__entry__author">Giuseppe Perrone, </li><li class="list-inline-item cited-by__entry__author">Chiara Taffon, </li><li class="list-inline-item cited-by__entry__author">Massimo Milione, </li><li class="list-inline-item cited-by__entry__author">Federica Grillo, </li><li class="list-inline-item cited-by__entry__author">Luca Mastracci, </li><li class="list-inline-item cited-by__entry__author">Alessandro Vanoli, </li><li class="list-inline-item cited-by__entry__author">Paola Parente, </li><li class="list-inline-item cited-by__entry__author">Matteo Fassan, </li></ul><span class="cited-by__entry__title">Immunohistochemical biomarker scoring in gastroesophageal cancers: Can computers help us?, </span><span class="cited-by__entry__series-title">Pathology - Research and Practice, </span><span class="cited-by__entry__volume"><strong>272</strong>, </span><span class="cited-by__entry__page-range">(156068), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.prp.2025.156068" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.prp.2025.156068</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.prp.2025.156068" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Wenqian Zheng, </li><li class="list-inline-item cited-by__entry__author">Yang Liu, </li><li class="list-inline-item cited-by__entry__author">Jinru Liu, </li><li class="list-inline-item cited-by__entry__author">Yuping Zhao, </li><li class="list-inline-item cited-by__entry__author">Peiyu Wang, </li><li class="list-inline-item cited-by__entry__author">Yi Wang, </li><li class="list-inline-item cited-by__entry__author">Yuxuan Wang, </li><li class="list-inline-item cited-by__entry__author">Zeyu Lu, </li><li class="list-inline-item cited-by__entry__author">Xiaofan Liu, </li><li class="list-inline-item cited-by__entry__author">Yaru Shi, </li><li class="list-inline-item cited-by__entry__author">Na Zhou, </li><li class="list-inline-item cited-by__entry__author">FermÃ­n Eduardo GonzÃ¡lez, </li><li class="list-inline-item cited-by__entry__author">Hongchen Sun, </li><li class="list-inline-item cited-by__entry__author">Ding Zhou, </li><li class="list-inline-item cited-by__entry__author">Xiaowei Xu, </li></ul><span class="cited-by__entry__title">Copper/calcium co-doped carbon dots for targeted cancer therapy with dual-mode imaging and synergistic induction of cuproptosis and calcium-mediated apoptosis, </span><span class="cited-by__entry__series-title">Journal of Colloid and Interface Science, </span><span class="cited-by__entry__volume"><strong>690</strong>, </span><span class="cited-by__entry__page-range">(137337), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jcis.2025.137337" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jcis.2025.137337</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jcis.2025.137337" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Choong-kun Lee, </li><li class="list-inline-item cited-by__entry__author">Sejung Park, </li><li class="list-inline-item cited-by__entry__author">Yaeji Lee, </li><li class="list-inline-item cited-by__entry__author">Choa Yun, </li><li class="list-inline-item cited-by__entry__author">Moonki Hong, </li><li class="list-inline-item cited-by__entry__author">Chung Mo Nam, </li><li class="list-inline-item cited-by__entry__author">Hyun Cheol Chung, </li><li class="list-inline-item cited-by__entry__author">Sun Young Rha, </li></ul><span class="cited-by__entry__title">Efficacy of the first-line immune checkpoint inhibitor plus chemotherapy for gastroesophageal cancer: A meta-analysis of phase III trials including unreported PD-L1 subgroups, </span><span class="cited-by__entry__series-title">Cancer Letters, </span><span class="cited-by__entry__volume"><strong>623</strong>, </span><span class="cited-by__entry__page-range">(217718), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.canlet.2025.217718" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.canlet.2025.217718</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.canlet.2025.217718" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Takahito Sugase, </li><li class="list-inline-item cited-by__entry__author">Takashi Kanemura, </li><li class="list-inline-item cited-by__entry__author">Norihiro Matsuura, </li><li class="list-inline-item cited-by__entry__author">Tomohira Takeoka, </li><li class="list-inline-item cited-by__entry__author">Yuki Ushimaru, </li><li class="list-inline-item cited-by__entry__author">Yasunori Masuike, </li><li class="list-inline-item cited-by__entry__author">Yoshitomo Yanagimoto, </li><li class="list-inline-item cited-by__entry__author">Kazuyoshi Yamamoto, </li><li class="list-inline-item cited-by__entry__author">Takeshi Omori, </li><li class="list-inline-item cited-by__entry__author">Ryota Mori, </li><li class="list-inline-item cited-by__entry__author">Masatoshi Kitakaze, </li><li class="list-inline-item cited-by__entry__author">Masahiko Kubo, </li><li class="list-inline-item cited-by__entry__author">Yosuke Mukai, </li><li class="list-inline-item cited-by__entry__author">Hisateru Komatsu, </li><li class="list-inline-item cited-by__entry__author">Toshinori Sueda, </li><li class="list-inline-item cited-by__entry__author">Yoshinori Kagawa, </li><li class="list-inline-item cited-by__entry__author">Hiroshi Wada, </li><li class="list-inline-item cited-by__entry__author">Kunihito Goto, </li><li class="list-inline-item cited-by__entry__author">Masayoshi Yasui, </li><li class="list-inline-item cited-by__entry__author">Hiroshi Miyata, </li></ul><span class="cited-by__entry__title">Safety and short-term outcomes of adjuvant nivolumab therapy at 480 mg dose every four weeks in resected esophageal cancer: a prospective cohort study, </span><span class="cited-by__entry__series-title">Esophagus, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s10388-025-01137-4" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s10388-025-01137-4</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s10388-025-01137-4" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Hazem Aboaid, </li><li class="list-inline-item cited-by__entry__author">Taimur Khalid, </li><li class="list-inline-item cited-by__entry__author">Abbas Hussain, </li><li class="list-inline-item cited-by__entry__author">Yin Mon Myat, </li><li class="list-inline-item cited-by__entry__author">Rishi Kumar Nanda, </li><li class="list-inline-item cited-by__entry__author">Ramaditya Srinivasmurthy, </li><li class="list-inline-item cited-by__entry__author">Kevin Nguyen, </li><li class="list-inline-item cited-by__entry__author">Daniel Thomas Jones, </li><li class="list-inline-item cited-by__entry__author">JoâLawrence Bigcas, </li><li class="list-inline-item cited-by__entry__author">Kyaw Zin Thein, </li></ul><span class="cited-by__entry__title">Advances and challenges in immunotherapy in head and neck cancer, </span><span class="cited-by__entry__series-title">Frontiers in Immunology, </span><span class="cited-by__entry__volume"><strong>16</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3389/fimmu.2025.1596583" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fimmu.2025.1596583</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fimmu.2025.1596583" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Fausto Petrelli, </li><li class="list-inline-item cited-by__entry__author">Antonio Ghidini, </li><li class="list-inline-item cited-by__entry__author">Italo Sarno, </li><li class="list-inline-item cited-by__entry__author">Alessandro Iaculli, </li><li class="list-inline-item cited-by__entry__author">Angeli Irene, </li><li class="list-inline-item cited-by__entry__author">Giovanna Moleri, </li><li class="list-inline-item cited-by__entry__author">Mauro Rossitto, </li><li class="list-inline-item cited-by__entry__author">Lorenzo Dottorini, </li></ul><span class="cited-by__entry__title">Adding immune checkpoint inhibitors to chemotherapy in elderly cancer patients: Beneficial for many but not all?, </span><span class="cited-by__entry__series-title">Tumori Journal, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1177/03008916251328539" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1177/03008916251328539</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1177/03008916251328539" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Qiuping Chen, </li><li class="list-inline-item cited-by__entry__author">Quan Sun, </li><li class="list-inline-item cited-by__entry__author">Baixue Li, </li></ul><span class="cited-by__entry__title">Sugemalimab plus chemotherapy vs. chemotherapy for treatment of Chinese patients with esophageal squamous cell carcinoma: a cost effectiveness analysis to inform decision making, </span><span class="cited-by__entry__series-title">Frontiers in Oncology, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3389/fonc.2025.1459695" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fonc.2025.1459695</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fonc.2025.1459695" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Takashi Matsumura, </li><li class="list-inline-item cited-by__entry__author">Kenji Tsuchihashi, </li><li class="list-inline-item cited-by__entry__author">Takeo Yamamoto, </li><li class="list-inline-item cited-by__entry__author">Fumiaki Jinnouchi, </li><li class="list-inline-item cited-by__entry__author">Wataru Kusano, </li><li class="list-inline-item cited-by__entry__author">Yota Kusumoto, </li><li class="list-inline-item cited-by__entry__author">Kohei Arimizu, </li><li class="list-inline-item cited-by__entry__author">Hirofumi Ohmura, </li><li class="list-inline-item cited-by__entry__author">Yuki Kuma, </li><li class="list-inline-item cited-by__entry__author">Shohei Moriyama, </li><li class="list-inline-item cited-by__entry__author">Kyoko Yamaguchi, </li><li class="list-inline-item cited-by__entry__author">Mamoru Ito, </li><li class="list-inline-item cited-by__entry__author">Taichi Isobe, </li><li class="list-inline-item cited-by__entry__author">Hiroshi Ariyama, </li><li class="list-inline-item cited-by__entry__author">Yoshinao Oda, </li><li class="list-inline-item cited-by__entry__author">Koichi Akashi, </li><li class="list-inline-item cited-by__entry__author">Eishi Baba, </li></ul><span class="cited-by__entry__title">Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab, </span><span class="cited-by__entry__series-title">Internal Medicine, </span><span class="cited-by__entry__volume"><strong>64</strong>, </span><span class="cited-by__entry__issue">11, </span><span class="cited-by__entry__page-range">(1728-1732), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.2169/internalmedicine.3743-24" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.2169/internalmedicine.3743-24</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.2169/internalmedicine.3743-24" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Zhihao Lu, </li><li class="list-inline-item cited-by__entry__author">Wenting Du, </li><li class="list-inline-item cited-by__entry__author">Xi Jiao, </li><li class="list-inline-item cited-by__entry__author">Yanni Wang, </li><li class="list-inline-item cited-by__entry__author">Jingwen Shi, </li><li class="list-inline-item cited-by__entry__author">Yang Shi, </li><li class="list-inline-item cited-by__entry__author">Yongqian Shu, </li><li class="list-inline-item cited-by__entry__author">Zuoxing Niu, </li><li class="list-inline-item cited-by__entry__author">Hiroki Hara, </li><li class="list-inline-item cited-by__entry__author">Jun Wu, </li><li class="list-inline-item cited-by__entry__author">Chih-Hung Hsu, </li><li class="list-inline-item cited-by__entry__author">Eric Van Cutsem, </li><li class="list-inline-item cited-by__entry__author">Malcolm V. Brock, </li><li class="list-inline-item cited-by__entry__author">Zhang Zhang, </li><li class="list-inline-item cited-by__entry__author">Ningning Ding, </li><li class="list-inline-item cited-by__entry__author">Yun Zhang, </li><li class="list-inline-item cited-by__entry__author">Zhirong Shen, </li><li class="list-inline-item cited-by__entry__author">Lin Shen, </li></ul><span class="cited-by__entry__title">
                  NOTCH1
              Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial
            , </span><span class="cited-by__entry__series-title">Journal of Clinical Oncology, </span><span class="cited-by__entry__volume"><strong>43</strong>, </span><span class="cited-by__entry__issue">16, </span><span class="cited-by__entry__page-range">(1898-1909), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1200/JCO-24-01818" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1200/JCO-24-01818</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1200/JCO-24-01818" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Xavier Bonfill Cosp, </li><li class="list-inline-item cited-by__entry__author">Olga Savall-Esteve, </li><li class="list-inline-item cited-by__entry__author">Javier Bracchiglione, </li><li class="list-inline-item cited-by__entry__author">Carolina Requeijo, </li><li class="list-inline-item cited-by__entry__author">Marilina Santero, </li></ul><span class="cited-by__entry__title">Mismatch between evidence and related clinical recommendations about the treatment of advanced esophageal cancer patients with anticancer drugs: A critical historical review, </span><span class="cited-by__entry__series-title">Journal of Cancer Policy, </span><span class="cited-by__entry__volume"><strong>44</strong>, </span><span class="cited-by__entry__page-range">(100580), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jcpo.2025.100580" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jcpo.2025.100580</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jcpo.2025.100580" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.386.issue-5%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2111380%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2111380" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2111380" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2111380.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f0"><figure class="graphic"><a class="open-in-viewer" href="#f0" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2111380_f0.jpg"><img src="/cms/10.1056/NEJMoa2111380/asset/8c19b16a-fc05-4e40-beb9-732de1ccb47c/assets/images/large/nejmoa2111380_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f0"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2111380_f0.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2111380_f1.jpg"><img src="/cms/10.1056/NEJMoa2111380/asset/b46d9399-dbd4-4138-97a7-d8827026288e/assets/images/large/nejmoa2111380_f1.jpg" height="3438" width="2259" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Overall Survival and Progression-free Survival with Nivolumab plus Chemotherapy as Compared with Chemotherapy Alone.</div><div class="notes"><div role="doc-footnote">Shown are KaplanâMeier estimates of overall survival in patients with tumor-cell programmed death ligand 1 (PD-L1) expression of 1% or greater (Panel A) and in the overall population (Panel B) and KaplanâMeier estimates of progression-free survival (as assessed by blinded independent central review) in patients with tumor-cell PD-L1 expression of 1% or greater (Panel C) and in the overall population (Panel D). The P value for the analysis of progression-free survival in the overall population did not meet the prespecified boundary for significance. Symbols indicate censored data.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2111380_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2111380_f2.jpg"><img src="/cms/10.1056/NEJMoa2111380/asset/2295f8d9-17e1-43cd-b70c-08421da6ab1e/assets/images/large/nejmoa2111380_f2.jpg" height="3438" width="2259" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Overall Survival and Progression-free Survival with Nivolumab plus Ipilimumab as Compared with Chemotherapy.</div><div class="notes"><div role="doc-footnote">Shown are KaplanâMeier estimates of overall survival in patients with tumor-cell PD-L1 expression of 1% or greater (Panel A) and in the overall population (Panel B) and KaplanâMeier estimates of progression-free survival (as assessed by blinded independent central review) in patients with tumor-cell PD-L1 expression of 1% or greater (Panel C) and in the overall population (Panel D). Symbols indicate censored data.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2111380_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2111380_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2111380/asset/5f5b6e27-8e6d-4783-a75e-6f86aef64adc/assets/images/large/nejmoa2111380_t1.jpg" height="2433" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Nivolumab plus Chemotherapy<br>(N=321)</th><th class="txxx-borders">Nivolumab plus Ipilimumab<br>(N=325)</th><th class="txxr-borders">Chemotherapy (N=324)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age (range) â yr</td><td class="xxxx-borders shading">64 (40â90)</td><td class="xxxx-borders shading">63 (28â81)</td><td class="xxxr-borders shading">64 (26â81)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex â no. (%)</td><td class="xxxx-borders">253 (79)</td><td class="xxxx-borders">269 (83)</td><td class="xxxr-borders">275 (85)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race â no. (%)<a href="#core-t1fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Asian</td><td class="xxxx-borders">227 (71)</td><td class="xxxx-borders">231 (71)</td><td class="xxxr-borders">227 (70)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">White</td><td class="xxxx-borders shading">85 (26)</td><td class="xxxx-borders shading">79 (24)</td><td class="xxxr-borders shading">84 (26)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Black</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxx-borders">4 (1)</td><td class="xxxr-borders">6 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">8 (2)</td><td class="xxxx-borders shading">11 (3)</td><td class="xxxr-borders shading">7 (2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Geographic region â no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Asia</td><td class="xxxx-borders shading">225 (70)</td><td class="xxxx-borders shading">229 (70)</td><td class="xxxr-borders shading">226 (70)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Region other than Asia</td><td class="xxxx-borders">96 (30)</td><td class="xxxx-borders">96 (30)</td><td class="xxxr-borders">98 (30)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">ECOG performance-status score â no. (%)<a href="#core-t1fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">0</td><td class="xxxx-borders">150 (47)</td><td class="xxxx-borders">151 (46)</td><td class="xxxr-borders">154 (48)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">171 (53)</td><td class="xxxx-borders shading">174 (54)</td><td class="xxxr-borders shading">170 (52)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Histologic type at initial diagnosis, squamous-cell carcinoma â no. (%)<a href="#core-t1fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">311 (97)</td><td class="xxxx-borders">322 (&gt;99)</td><td class="xxxr-borders">318 (98)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Tumor-cell PD-L1 expression â no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">&lt;1% or indeterminate<a href="#core-t1fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders">163 (51)</td><td class="xxxx-borders">167 (51)</td><td class="xxxr-borders">167 (52)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">â¥1%</td><td class="xxxx-borders shading">158 (49)</td><td class="xxxx-borders shading">158 (49)</td><td class="xxxr-borders shading">157 (48)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Disease status at trial entry â no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Metastatic</td><td class="xxxx-borders shading">184 (57)</td><td class="xxxx-borders shading">196 (60)</td><td class="xxxr-borders shading">187 (58)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Recurrent, locoregional</td><td class="xxxx-borders">21 (7)</td><td class="xxxx-borders">25 (8)</td><td class="xxxr-borders">25 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Recurrent, distant</td><td class="xxxx-borders shading">72 (22)</td><td class="xxxx-borders shading">73 (22)</td><td class="xxxr-borders shading">60 (19)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Unresectable advanced</td><td class="xxxx-borders">44 (14)</td><td class="xxxx-borders">31 (10)</td><td class="xxxr-borders">52 (16)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Number of organs with metastases â no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">â¤1</td><td class="xxxx-borders">158 (49)</td><td class="xxxx-borders">160 (49)</td><td class="xxxr-borders">158 (49)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">â¥2</td><td class="xxxx-borders shading">163 (51)</td><td class="xxxx-borders shading">165 (51)</td><td class="xxxr-borders shading">166 (51)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Smoking status â no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Current or former smoker</td><td class="xxxx-borders shading">254 (79)</td><td class="xxxx-borders shading">268 (82)</td><td class="xxxr-borders shading">256 (79)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Never smoked</td><td class="xbxx-borders">67 (21)</td><td class="xbxx-borders">57 (18)</td><td class="xbxr-borders">68 (21)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">The overall population includes all the patients who underwent randomization. Randomization was stratified according to tumor-cell programmed death ligand 1 (PD-L1) expression status (â¥1% vs. &lt;1% or indeterminate), geographic region (East Asia [Japan, Korea, and Taiwan] vs. rest of Asia vs. rest of world), Eastern Cooperative Oncology Group (ECOG) performance-status score (0 vs. 1), and number of organs with metastases (â¤1 vs. â¥2). Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race was reported by the patients.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">ECOG performance-status scores range from 0 to 5, with higher scores indicating greater disability.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">A total of 9 patients who received nivolumab plus chemotherapy, 3 patients who received nivolumab plus ipilimumab, and 6 patients who received chemotherapy alone had adenosquamous-cell carcinoma of the esophagus. One patient who had been assigned to receive nivolumab plus chemotherapy had sarcomatoid carcinoma of the esophagus and underwent randomization but was not treated.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">Three patients who received nivolumab plus ipilimumab and 2 patients who received chemotherapy alone had indeterminate tumor-cell PD-L1 expression at baseline.</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Clinical Characteristics of the Overall Population at Baseline.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2111380_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2111380_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2111380/asset/245eea64-8dca-4dd9-bbf7-e3912fd97720/assets/images/large/nejmoa2111380_t2.jpg" height="1210" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders" colspan="3"><span>Patients with Tumor-Cell PD-L1 Expression of â¥1%</span></th><th class="txxr-borders" colspan="3"><span>Overall Population</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Nivolumab plus Chemotherapy<br>(N=158)</th><th class="xxxx-borders">Nivolumab plus Ipilimumab<br>(N=158)</th><th class="xxxx-borders">Chemotherapy<br>(N=157)</th><th class="xxxx-borders">Nivolumab plus Chemotherapy<br>(N=321)</th><th class="xxxx-borders">Nivolumab plus Ipilimumab<br>(N=325)</th><th class="xxxr-borders">Chemotherapy<br>(N=324)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Objective response rate</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients (%)</td><td class="xxxx-borders">84 (53)</td><td class="xxxx-borders">56 (35)</td><td class="xxxx-borders">31 (20)</td><td class="xxxx-borders">152 (47)</td><td class="xxxx-borders">90 (28)</td><td class="xxxr-borders">87 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">95% CI</td><td class="xxxx-borders shading">45â61</td><td class="xxxx-borders shading">28â43</td><td class="xxxx-borders shading">14â27</td><td class="xxxx-borders shading">42â53</td><td class="xxxx-borders shading">23â33</td><td class="xxxr-borders shading">22â32</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Best overall response â no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Complete response</td><td class="xxxx-borders shading">26 (16)</td><td class="xxxx-borders shading">28 (18)</td><td class="xxxx-borders shading">8 (5)</td><td class="xxxx-borders shading">43 (13)</td><td class="xxxx-borders shading">36 (11)</td><td class="xxxr-borders shading">20 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Partial response</td><td class="xxxx-borders">58 (37)</td><td class="xxxx-borders">28 (18)</td><td class="xxxx-borders">23 (15)</td><td class="xxxx-borders">109 (34)</td><td class="xxxx-borders">54 (17)</td><td class="xxxr-borders">67 (21)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Stable disease</td><td class="xxxx-borders shading">40 (25)</td><td class="xxxx-borders shading">43 (27)</td><td class="xxxx-borders shading">72 (46)</td><td class="xxxx-borders shading">103 (32)</td><td class="xxxx-borders shading">103 (32)</td><td class="xxxr-borders shading">148 (46)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Progressive disease</td><td class="xxxx-borders">22 (14)</td><td class="xxxx-borders">48 (30)</td><td class="xxxx-borders">24 (15)</td><td class="xxxx-borders">42 (13)</td><td class="xxxx-borders">103 (32)</td><td class="xxxr-borders">38 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Could not be evaluated</td><td class="xxxx-borders shading">12 (8)</td><td class="xxxx-borders shading">11 (7)</td><td class="xxxx-borders shading">30 (19)</td><td class="xxxx-borders shading">24 (7)</td><td class="xxxx-borders shading">29 (9)</td><td class="xxxr-borders shading">51 (16)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median time to response (range) â mo<a href="#core-t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders">1.5 (0.6â4.3)</td><td class="xxxx-borders">1.5 (1.2â8.4)</td><td class="xxxx-borders">1.5 (1.3â9.7)</td><td class="xxxx-borders">1.5 (0.6â6.8)</td><td class="xxxx-borders">1.5 (1.2â8.4)</td><td class="xxxr-borders">1.5 (1.1â9.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median duration of response (95% CI) â mo<a href="#core-t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">8.4 (6.9â12.4)</td><td class="xxxx-borders shading">11.8 (7.1â27.4)</td><td class="xxxx-borders shading">5.7 (4.4â8.7)</td><td class="xxxx-borders shading">8.2 (6.9â9.7)</td><td class="xxxx-borders shading">11.1 (8.3â14.0)</td><td class="xxxr-borders shading">7.1 (5.7â8.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Patients with ongoing response â no. (%)<a href="#core-t2fn2" role="doc-noteref">â </a></td><td class="xbxx-borders">11 (13)</td><td class="xbxx-borders">14 (25)</td><td class="xbxx-borders">1 (3)</td><td class="xbxx-borders">26 (17)</td><td class="xbxx-borders">20 (22)</td><td class="xbxr-borders">5 (6)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Included are all patients who underwent randomization and had target-lesion measurements at baseline, as assessed by blinded independent central review. Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">This analysis included only patients who had an objective response.</div></div></div></figcaption></a><figcaption><div class="caption">Antitumor Activity, as Assessed by Blinded Independent Central Review.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2111380_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2111380_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2111380/asset/cd6bd818-93fa-4c56-aa39-b6344b20dea4/assets/images/large/nejmoa2111380_t3.jpg" height="2578" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="2"><span>Nivolumab plus<br>Chemotherapy<br>(N=310)</span></th><th class="txxx-borders" colspan="2"><span>Nivolumab plus<br>Ipilimumab<br>(N=322)</span></th><th class="txxr-borders" colspan="2"><span>Chemotherapy<br>(N=304)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 3 or 4</th><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 3 or 4</th><th class="xxxx-borders">Any Grade</th><th class="xxxr-borders">Grade 3 or 4</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="6"><span>number of patients with event (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any treatment-related adverse event</td><td class="xxxx-borders shading">297 (96)</td><td class="xxxx-borders shading">147 (47)</td><td class="xxxx-borders shading">256 (80)</td><td class="xxxx-borders shading">102 (32)</td><td class="xxxx-borders shading">275 (90)</td><td class="xxxr-borders shading">108 (36)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Treatment-related serious adverse event</td><td class="xxxx-borders">74 (24)</td><td class="xxxx-borders">57 (18)</td><td class="xxxx-borders">103 (32)</td><td class="xxxx-borders">73 (23)</td><td class="xxxx-borders">49 (16)</td><td class="xxxr-borders">38 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Treatment-related adverse event leading to trial-drug discontinuation<a href="#core-t3fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">106 (34)</td><td class="xxxx-borders shading">29 (9)</td><td class="xxxx-borders shading">57 (18)</td><td class="xxxx-borders shading">41 (13)</td><td class="xxxx-borders shading">59 (19)</td><td class="xxxr-borders shading">14 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Treatment-related adverse event leading to death<a href="#core-t3fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">5 (2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">8 (2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">6 (2)</td><td class="xxxr-borders">â</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Treatment-related adverse events reported in â¥10% of patients in any group</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nausea</td><td class="xxxx-borders">182 (59)</td><td class="xxxx-borders">11 (4)</td><td class="xxxx-borders">26 (8)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxx-borders">158 (52)</td><td class="xxxr-borders">8 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders shading">132 (43)</td><td class="xxxx-borders shading">13 (4)</td><td class="xxxx-borders shading">19 (6)</td><td class="xxxx-borders shading">5 (2)</td><td class="xxxx-borders shading">130 (43)</td><td class="xxxr-borders shading">9 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Stomatitis</td><td class="xxxx-borders">98 (32)</td><td class="xxxx-borders">20 (6)</td><td class="xxxx-borders">14 (4)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">71 (23)</td><td class="xxxr-borders">5 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Anemia</td><td class="xxxx-borders shading">93 (30)</td><td class="xxxx-borders shading">30 (10)</td><td class="xxxx-borders shading">12 (4)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">67 (22)</td><td class="xxxr-borders shading">17 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Decreased neutrophil count</td><td class="xxxx-borders">65 (21)</td><td class="xxxx-borders">25 (8)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">52 (17)</td><td class="xxxr-borders">24 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Fatigue</td><td class="xxxx-borders shading">61 (20)</td><td class="xxxx-borders shading">7 (2)</td><td class="xxxx-borders shading">29 (9)</td><td class="xxxx-borders shading">4 (1)</td><td class="xxxx-borders shading">50 (16)</td><td class="xxxr-borders shading">11 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">60 (19)</td><td class="xxxx-borders">3 (1)</td><td class="xxxx-borders">32 (10)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">46 (15)</td><td class="xxxr-borders">6 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">59 (19)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">7 (2)</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxx-borders shading">66 (22)</td><td class="xxxr-borders shading">1 (&lt;1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Vomiting</td><td class="xxxx-borders">56 (18)</td><td class="xxxx-borders">7 (2)</td><td class="xxxx-borders">18 (6)</td><td class="xxxx-borders">4 (1)</td><td class="xxxx-borders">49 (16)</td><td class="xxxr-borders">9 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Malaise</td><td class="xxxx-borders shading">50 (16)</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxx-borders shading">12 (4)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">45 (15)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Decreased white-cell count</td><td class="xxxx-borders">43 (14)</td><td class="xxxx-borders">11 (4)</td><td class="xxxx-borders">3 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">28 (9)</td><td class="xxxr-borders">6 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hiccups</td><td class="xxxx-borders shading">42 (14)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">53 (17)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Increased blood creatinine level</td><td class="xxxx-borders">39 (13)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxx-borders">5 (2)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">32 (11)</td><td class="xxxr-borders">1 (&lt;1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Decreased platelet count</td><td class="xxxx-borders shading">36 (12)</td><td class="xxxx-borders shading">3 (1)</td><td class="xxxx-borders shading">6 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">32 (11)</td><td class="xxxr-borders shading">5 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mucosal inflammation</td><td class="xxxx-borders">33 (11)</td><td class="xxxx-borders">8 (3)</td><td class="xxxx-borders">4 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">26 (9)</td><td class="xxxr-borders">4 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Alopecia</td><td class="xxxx-borders shading">31 (10)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">32 (11)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Rash</td><td class="xxxx-borders">24 (8)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxx-borders">55 (17)</td><td class="xxxx-borders">7 (2)</td><td class="xxxx-borders">5 (2)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pruritus</td><td class="xxxx-borders shading">23 (7)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">43 (13)</td><td class="xxxx-borders shading">3 (1)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Hypothyroidism</td><td class="xbxx-borders">18 (6)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">43 (13)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxr-borders">0</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Included are all the patients who received at least one dose of the assigned treatment. All events were reported between the first dose of treatment and 30 days after the last dose of treatment. Any relation between treatment and adverse events reported in the patients who received nivolumab plus chemotherapy was attributed to either nivolumab or any of the chemotherapies or both. Any relation between treatment and adverse events reported in the patients who received nivolumab plus ipilimumab was attributed to either nivolumab or ipilimumab or both. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0, and the <i>Medical Dictionary for Regulatory Activities</i>, version 23.1.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">This category refers to adverse events leading to discontinuation of any drug in the regimen.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">Treatment-related adverse events leading to death were reported regardless of time frame. Treatment-related deaths in the group that received nivolumab plus chemotherapy were from acute kidney injury, pneumonia, pneumonitis, pneumonitis or respiratory-tract infection, and pneumatosis intestinalis (in 1 patient each). Treatment-related deaths in the group that received nivolumab plus ipilimumab were from pneumonitis (in 2 patients) and acute respiratory distress syndrome, interstitial lung disease, and pulmonary embolism (in 1 patient each). In addition, three deaths in the group that received nivolumab plus ipilimumab (one from other reasons and two from disease) were also reported by the investigator as treatment-related serious adverse events that eventually had a fatal outcome (acute kidney injury, general physical health deterioration, and internal hemorrhage). Treatment-related deaths in the group that received chemotherapy alone were from acute kidney injury, pneumonia, sepsis, and septic shock (in 1 patient each). Two additional deaths in the chemotherapy group (one from other reasons and one from an unknown cause) were also reported by the investigator as treatment-related serious adverse events that eventually had a fatal outcome (acute respiratory failure and death).</div></div></div></figcaption></a><figcaption><div class="caption">Treatment-Related Adverse Events in All the Patients Who Received Trial Treatment.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2111380_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2111380</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <em>CA Cancer J Clin</em> 2021;71:209-249.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3322/caac.21660" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33538338/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000614520100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+cancer+statistics+2020%3A+GLOBOCAN+estimates+of+incidence+and+mortality+worldwide+for+36+cancers+in+185+countries.&amp;publication_year=2021&amp;journal=CA+Cancer+J+Clin&amp;pages=209-249&amp;doi=10.3322%2Fcaac.21660&amp;pmid=33538338" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Arnold M, Ferlay J, van Berge Henegouwen MI, Soerjomataram I. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. <em>Gut</em> 2020;69:1564-1571.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/gutjnl-2020-321600" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32606208/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000567562200026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+burden+of+oesophageal+and+gastric+cancer+by+histology+and+subsite+in+2018.&amp;publication_year=2020&amp;journal=Gut&amp;pages=1564-1571&amp;doi=10.1136%2Fgutjnl-2020-321600&amp;pmid=32606208" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Smyth EC, Lagergren J, Fitzgerald RC, et al. Oesophageal cancer. <em>Nat Rev Dis Primers</em> 2017;3:17048-17048.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrdp.2017.48" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28748917/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000407302400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Oesophageal+cancer.&amp;publication_year=2017&amp;journal=Nat+Rev+Dis+Primers&amp;pages=17048-17048&amp;doi=10.1038%2Fnrdp.2017.48&amp;pmid=28748917" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Cancer Research UK. Oesophageal cancer incidence (<a href="https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/oesophageal-cancer#heading-Zero">https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/oesophageal-cancer#heading-Zero</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Cancer+Research+UK.+Oesophageal+cancer+incidence+%28https%3A%2F%2Fwww.cancerresearchuk.org%2Fhealth-professional%2Fcancer-statistics%2Fstatistics-by-cancer-type%2Foesophageal-cancer%23heading-Zero%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Patel N, Benipal B. Incidence of esophageal cancer in the United States from 2001â2015: a United States cancer statistics analysis of 50 states. <em>Cureus</em> 2018;10(12):e3709-e3709.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30788198/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000461069500015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Incidence+of+esophageal+cancer+in+the+United+States+from+2001%E2%80%932015%3A+a+United+States+cancer+statistics+analysis+of+50+states.&amp;publication_year=2018&amp;journal=Cureus&amp;pages=e3709-e3709&amp;pmid=30788198" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2012. <em>Esophagus</em> 2019;16:221-245.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10388-019-00674-z" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31098822/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000472853200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comprehensive+registry+of+esophageal+cancer+in+Japan%2C+2012.&amp;publication_year=2019&amp;journal=Esophagus&amp;pages=221-245&amp;doi=10.1007%2Fs10388-019-00674-z&amp;pmid=31098822" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. <em>Eur J Cancer</em> 1997;33:1216-1220.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0959-8049(97)00088-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9301445/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1997XR38300020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomised+phase+II+study+of+cisplatin+and+5-fluorouracil+%285-FU%29+versus+cisplatin+alone+in+advanced+squamous+cell+oesophageal+cancer.&amp;publication_year=1997&amp;journal=Eur+J+Cancer&amp;pages=1216-1220&amp;doi=10.1016%2FS0959-8049%2897%2900088-9&amp;pmid=9301445" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] outcomes (median survival, &lt;1 year). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] limited interpretation of the results. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Lee SJ, Kim S, Kim M, et al. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study. <em>BMC Cancer</em> 2015;15:693-693.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s12885-015-1716-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26468007/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000362705500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Capecitabine+in+combination+with+either+cisplatin+or+weekly+paclitaxel+as+a+first-line+treatment+for+metastatic+esophageal+squamous+cell+carcinoma%3A+a+randomized+phase+II+study.&amp;publication_year=2015&amp;journal=BMC+Cancer&amp;pages=693-693&amp;doi=10.1186%2Fs12885-015-1716-9&amp;pmid=26468007" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] outcomes (median survival, &lt;1 year). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] limited interpretation of the results. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Moehler M, Maderer A, Thuss-Patience PC, et al. Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). <em>Ann Oncol</em> 2020;31:228-235.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.annonc.2019.10.018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31959339/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000516712400010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cisplatin+and+5-fluorouracil+with+or+without+epidermal+growth+factor+receptor+inhibition+panitumumab+for+patients+with+non-resectable%2C+advanced+or+metastatic+oesophageal+squamous+cell+cancer%3A+a+prospective%2C+open-label%2C+randomised+phase+III+AIO%2FEORTC+trial+%28POWER%29.&amp;publication_year=2020&amp;journal=Ann+Oncol&amp;pages=228-235&amp;doi=10.1016%2Fj.annonc.2019.10.018&amp;pmid=31959339" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] outcomes (median survival, &lt;1 year). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] limited interpretation of the results. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r38" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] the individual components at similar doses. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. <em>Esophagus</em> 2019;16:1-24.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10388-018-0641-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30171413/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457767800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Esophageal+cancer+practice+guidelines+2017+edited+by+the+Japan+Esophageal+Society%3A+part+1.&amp;publication_year=2019&amp;journal=Esophagus&amp;pages=1-24&amp;doi=10.1007%2Fs10388-018-0641-9&amp;pmid=30171413" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Lordick F, Mariette C, Haustermans K, ObermannovÃ¡ R, Arnold D. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <em>Ann Oncol</em> 2016;27:Suppl 5:v50-v57.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdw329" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27664261/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000385125200004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Oesophageal+cancer%3A+ESMO+clinical+practice+guidelines+for+diagnosis%2C+treatment+and+follow-up.&amp;publication_year=2016&amp;journal=Ann+Oncol&amp;pages=v50-v57&amp;doi=10.1093%2Fannonc%2Fmdw329&amp;pmid=27664261" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Clinical practice guidelines in oncology: esophageal and esophagogastric junction cancers, version 1. Plymouth Meeting, PA: National Comprehensive Cancer Network, 2022.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Clinical+practice+guidelines+in+oncology%3A+esophageal+and+esophagogastric+junction+cancers%2C+version+1.+Plymouth+Meeting%2C+PA%3A+National+Comprehensive+Cancer+Network%2C+2022." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r13" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] used first-line treatment for decades, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] irrespective of PD-L1 expression status. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">National Health Commission of the Peopleâs Republic of China. Chinese guidelines for diagnosis and treatment of esophageal carcinoma 2018 (English version). <em>Chin J Cancer Res</em> 2019;31:223-258.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.21147/j.issn.1000-9604.2019.02.01" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31156297/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000473282800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Chinese+guidelines+for+diagnosis+and+treatment+of+esophageal+carcinoma+2018+%28English+version%29.&amp;publication_year=2019&amp;journal=Chin+J+Cancer+Res&amp;pages=223-258&amp;doi=10.21147%2Fj.issn.1000-9604.2019.02.01&amp;pmid=31156297" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Xu R, Luo H, Lu J, et al. ESCORT-1st: a randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC). <em>J Clin Oncol</em> 2021;39:Suppl 15. abstract 4000.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2021.39.15_suppl.4000" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000708120602103" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ESCORT-1st%3A+a+randomized%2C+double-blind%2C+placebo-controlled%2C+phase+3+trial+of+camrelizumab+plus+chemotherapy+versus+chemotherapy+in+patients+with+untreated+advanced+or+metastatic+esophageal+squamous+cell+carcinoma+%28ESCC%29.&amp;publication_year=2021&amp;journal=J+Clin+Oncol&amp;doi=10.1200%2FJCO.2021.39.15_suppl.4000" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with chemotherapy over chemotherapy alone. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of adding a PD-1 inhibitor to chemotherapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] in patients with esophageal cancer. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Sun J-M, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. <em>Lancet</em> 2021;398:759-771.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(21)01234-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34454674/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000689712800025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+plus+chemotherapy+versus+chemotherapy+alone+for+first-line+treatment+of+advanced+oesophageal+cancer+%28KEYNOTE-590%29%3A+a+randomised%2C+placebo-controlled%2C+phase+3+study.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=759-771&amp;doi=10.1016%2FS0140-6736%2821%2901234-4&amp;pmid=34454674" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with chemotherapy over chemotherapy alone. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of adding a PD-1 inhibitor to chemotherapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] in patients with esophageal cancer. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Salem ME, Puccini A, Xiu J, et al. Comparative molecular analyses of esophageal squamous cell carcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma. <em>Oncologist</em> 2018;23:1319-1327.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1634/theoncologist.2018-0143" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29866946/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000449946000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+molecular+analyses+of+esophageal+squamous+cell+carcinoma%2C+esophageal+adenocarcinoma%2C+and+gastric+adenocarcinoma.&amp;publication_year=2018&amp;journal=Oncologist&amp;pages=1319-1327&amp;doi=10.1634%2Ftheoncologist.2018-0143&amp;pmid=29866946" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. <em>Lancet Oncol</em> 2019;20:1506-1517.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(19)30626-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31582355/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000493897500042" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+versus+chemotherapy+in+patients+with+advanced+oesophageal+squamous+cell+carcinoma+refractory+or+intolerant+to+previous+chemotherapy+%28ATTRACTION-3%29%3A+a+multicentre%2C+randomised%2C+open-label%2C+phase+3+trial.&amp;publication_year=2019&amp;journal=Lancet+Oncol&amp;pages=1506-1517&amp;doi=10.1016%2FS1470-2045%2819%2930626-6&amp;pmid=31582355" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] 50% of patients with advanced disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] irrespective of PD-L1 expression status. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r32" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] esophageal squamous-cell carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r33" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] which is consistent with previous reports. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] with esophageal squamous-cell carcinoma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r37" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] treatment effect relative to chemotherapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r38" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] the individual components at similar doses. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. <em>Lancet</em> 2021;398:27-40.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(21)00797-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34102137/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000668969500027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-line+nivolumab+plus+chemotherapy+versus+chemotherapy+alone+for+advanced+gastric%2C+gastro-oesophageal+junction%2C+and+oesophageal+adenocarcinoma+%28CheckMate+649%29%3A+a+randomised%2C+open-label%2C+phase+3+trial.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=27-40&amp;doi=10.1016%2FS0140-6736%2821%2900797-2&amp;pmid=34102137" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced nonâsmall-cell lung cancer. <em>N Engl J Med</em> 2019;381:2020-2031.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_20_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2111380&amp;key=10.1056%2FNEJMoa1910231&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31562796/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000505218800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+plus+ipilimumab+in+advanced+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=2020-2031&amp;doi=10.1056%2FNEJMoa1910231&amp;pmid=31562796" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] monotherapy in multiple solid tumors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r38" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the individual components at similar doses. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. <em>N Engl J Med</em> 2017;377:1345-1356.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_21_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2111380&amp;key=10.1056%2FNEJMoa1709684&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28889792/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000412375000014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Overall+survival+with+combined+nivolumab+and+ipilimumab+in+advanced+melanoma.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=1345-1356&amp;doi=10.1056%2FNEJMoa1709684&amp;pmid=28889792" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <em>Lancet</em> 2021;397:375-386.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)32714-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33485464/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000614227700025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-line+nivolumab+plus+ipilimumab+in+unresectable+malignant+pleural+mesothelioma+%28CheckMate+743%29%3A+a+multicentre%2C+randomised%2C+open-label%2C+phase+3+trial.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=375-386&amp;doi=10.1016%2FS0140-6736%2820%2932714-8&amp;pmid=33485464" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] monotherapy in multiple solid tumors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] frequencies expected with this combination. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Darling G, Eton DT, Sulman J, Casson AG, Celia D. Validation of the functional assessment of cancer therapy esophageal cancer subscale. <em>Cancer</em> 2006;107:854-863.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/cncr.22055" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16826587/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000239950000024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Validation+of+the+functional+assessment+of+cancer+therapy+esophageal+cancer+subscale.&amp;publication_year=2006&amp;journal=Cancer&amp;pages=854-863&amp;doi=10.1002%2Fcncr.22055&amp;pmid=16826587" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Ringash J, OâSullivan B, Bezjak A, Redelmeier DA. Interpreting clinically significant changes in patient-reported outcomes. <em>Cancer</em> 2007;110:196-202.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/cncr.22799" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17546575/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000247384200024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interpreting+clinically+significant+changes+in+patient-reported+outcomes.&amp;publication_year=2007&amp;journal=Cancer&amp;pages=196-202&amp;doi=10.1002%2Fcncr.22799&amp;pmid=17546575" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. <em>Cancer Chemother Rep</em> 1966;50:163-170.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/5910392/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evaluation+of+survival+data+and+two+new+rank+order+statistics+arising+in+its+consideration.&amp;publication_year=1966&amp;journal=Cancer+Chemother+Rep&amp;pages=163-170&amp;pmid=5910392" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Peto R, Peto J. Asymptotically efficient rank invariant test procedures. <em>J R Stat Soc [Ser A]</em> 1972;135:185-207.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2307/2344317" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1972N166900020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Asymptotically+efficient+rank+invariant+test+procedures.&amp;publication_year=1972&amp;journal=J+R+Stat+Soc+%5BSer+A%5D&amp;pages=185-207&amp;doi=10.2307%2F2344317" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Cox DR. Regression models and life-tables. <em>J R Stat Soc [Ser B]</em> 1972;34:187-202.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.2517-6161.1972.tb00899.x" target="_blank">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Regression+models+and+life-tables.&amp;publication_year=1972&amp;journal=J+R+Stat+Soc+%5BSer+B%5D&amp;pages=187-202&amp;doi=10.1111%2Fj.2517-6161.1972.tb00899.x" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. <em>J Am Stat Assoc</em> 1958;53:457-481.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/01621459.1958.10501452" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1958WX09300012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nonparametric+estimation+from+incomplete+observations.&amp;publication_year=1958&amp;journal=J+Am+Stat+Assoc&amp;pages=457-481&amp;doi=10.1080%2F01621459.1958.10501452" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. <em>Biometrika</em> 1934;26:404-413.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/biomet/26.4.404" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000200863400002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+use+of+confidence+or+fiducial+limits+illustrated+in+the+case+of+the+binomial.&amp;publication_year=1934&amp;journal=Biometrika&amp;pages=404-413&amp;doi=10.1093%2Fbiomet%2F26.4.404" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Koch GG, Carr GJ, Amara IA, Stokes ME, Uryniak TJ. Categorical data analysis. In: Berry DA, ed. <em>Statistical methodology in the pharmaceutical sciences.</em> Boca Raton, FL: CRC Press, 1989:389-474.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Categorical+data+analysis.&amp;publication_year=1989&amp;pages=389-474" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Kojima T, Shah MA, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. <em>J Clin Oncol</em> 2020;38:4138-4148.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.20.01888" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33026938/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000598458500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized+phase+III+KEYNOTE-181+study+of+pembrolizumab+versus+chemotherapy+in+advanced+esophageal+cancer.&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;pages=4138-4148&amp;doi=10.1200%2FJCO.20.01888&amp;pmid=33026938" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigatorâs choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. <em>Lancet Oncol</em> 2020;21:832-842.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(20)30110-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32416073/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000544057400034" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Camrelizumab+versus+investigator%E2%80%99s+choice+of+chemotherapy+as+second-line+therapy+for+advanced+or+metastatic+oesophageal+squamous+cell+carcinoma+%28ESCORT%29%3A+a+multicentre%2C+randomised%2C+open-label%2C+phase+3+study.&amp;publication_year=2020&amp;journal=Lancet+Oncol&amp;pages=832-842&amp;doi=10.1016%2FS1470-2045%2820%2930110-8&amp;pmid=32416073" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. <em>Lancet Oncol</em> 2017;18:631-639.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(17)30181-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28314688/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000400401100051" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+treatment+for+oesophageal+squamous-cell+carcinoma%3A+an+open-label%2C+multicentre%2C+phase+2+trial.&amp;publication_year=2017&amp;journal=Lancet+Oncol&amp;pages=631-639&amp;doi=10.1016%2FS1470-2045%2817%2930181-X&amp;pmid=28314688" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="core-r33" class="citations"><div class="citation"><div class="citation-content">Kato K, Doki Y, Ura T, et al. Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. <em>Cancer Sci</em> 2020;111:1676-1684.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/cas.14380" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32160365/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000529314800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+efficacy+and+predictive+correlates+of+response+to+nivolumab+in+Japanese+patients+with+esophageal+cancer.&amp;publication_year=2020&amp;journal=Cancer+Sci&amp;pages=1676-1684&amp;doi=10.1111%2Fcas.14380&amp;pmid=32160365" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="core-r34" class="citations"><div class="citation"><div class="citation-content">Lei M, Siemers NO, Pandya D, et al. Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab Â± ipilimumab in gastric cancer/gastroesophageal junction cancer. <em>Clin Cancer Res</em> 2021;27:3926-3935.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-20-2790" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33782030/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000674703200017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Analyses+of+PD-L1+and+inflammatory+gene+expression+association+with+efficacy+of+nivolumab+%C2%B1+ipilimumab+in+gastric+cancer%2Fgastroesophageal+junction+cancer.&amp;publication_year=2021&amp;journal=Clin+Cancer+Res&amp;pages=3926-3935&amp;doi=10.1158%2F1078-0432.CCR-20-2790&amp;pmid=33782030" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="core-r35" class="citations"><div class="citation"><div class="citation-content">Kulangara K, Zhang N, Corigliano E, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. <em>Arch Pathol Lab Med</em> 2019;143:330-337.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.5858/arpa.2018-0043-OA" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30028179/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000459956200013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+utility+of+the+combined+positive+score+for+programmed+death+ligand-1+expression+and+the+approval+of+pembrolizumab+for+treatment+of+gastric+cancer.&amp;publication_year=2019&amp;journal=Arch+Pathol+Lab+Med&amp;pages=330-337&amp;doi=10.5858%2Farpa.2018-0043-OA&amp;pmid=30028179" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="core-r36" class="citations"><div class="citation"><div class="citation-content">Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous nonâsmall-cell lung cancer. <em>N Engl J Med</em> 2015;373:1627-1639.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r37"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_37_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2111380&amp;key=10.1056%2FNEJMoa1507643&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26412456/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000363317800008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+versus+docetaxel+in+advanced+nonsquamous+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=1627-1639&amp;doi=10.1056%2FNEJMoa1507643&amp;pmid=26412456" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="core-r37" class="citations"><div class="citation"><div class="citation-content">Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. <em>N Engl J Med</em> 2016;375:1856-1867.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r37"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_38_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2111380&amp;key=10.1056%2FNEJMoa1602252&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27718784/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000387534200009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+for+recurrent+squamous-cell+carcinoma+of+the+head+and+neck.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=1856-1867&amp;doi=10.1056%2FNEJMoa1602252&amp;pmid=27718784" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="core-r38" class="citations"><div class="citation"><div class="citation-content">Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group trial. <em>Jpn J Clin Oncol</em> 1992;22:172-176.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/1518165/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1992JL70600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+II+evaluation+of+cisplatin+and+5-fluorouracil+in+advanced+squamous+cell+carcinoma+of+the+esophagus%3A+a+Japanese+Esophageal+Oncology+Group+trial.&amp;publication_year=1992&amp;journal=Jpn+J+Clin+Oncol&amp;pages=172-176&amp;pmid=1518165" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 18, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2202880" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Nivolumab in Esophageal Squamous-Cell Carcinoma</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Braintree, Massachusetts</span></div><div><span>Pediatrics, General</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/893359/pediatric-urgent-care-physician-weekends/?query=fjwp&amp;rid=980">Pediatric Urgent Care Physician - Weekends</a></div></div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Graduate Training / Residency</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/509002/full-time-advanced-lung-disease-and-transplantation-clinical-research-fellow-/?query=fjwp&amp;rid=3059">Full-Time Advanced Lung Disease and Transplantation Clinical Research Fellow </a></div></div><div class="nejm-widget_item"><div><span> Port Matilda, Pennsylvania</span></div><div><span>Anesthesiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883803/anesthesiologist/?query=fjwf&amp;rid=764">Anesthesiologist</a></div></div><div class="nejm-widget_item"><div><span> Texas</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/881664/physician-internal-medicine/?query=fjwf&amp;rid=385607">Physician- Internal Medicine</a></div></div><div class="nejm-widget_item"><div><span> Maine</span></div><div><span>Surgery, General</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/879137/generalist-with-breast-surgery-focus-desirable-coastal-town-in-new-england/?query=fjwf&amp;rid=5263">Generalist with Breast Surgery Focus | Desirable Coastal Town in New England</a></div></div><div class="nejm-widget_item"><div><span> Lebanon, Kentucky</span></div><div><span>Emergency Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/873882/emergency-medicine-physician-in-lebanon-kentucky/?query=fjwf&amp;rid=4552">Emergency Medicine Physician in Lebanon, Kentucky</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128743&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Fnotablearticles2024%3Fpromo%3DONFQNAR4%26query%3Dcm-ra%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dna24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2111380&amp;pubId=41284186&amp;placeholderId=101337&amp;productId=1007"><img src="/sda/128743/rightRail--notable24_001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6bc3f84721a93-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6bc3f84721a93-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6bc3f84721a93-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$076821981$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$076821981$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$076821981$--></div></div><div class="mlt-body"><!--?lit$076821981$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$076821981$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$076821981$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$076821981$-->Nov 28, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2402141?query=recirc_Semantic" target="_self">Nivolumab plus Ipilimumab in Microsatellite-InstabilityâHigh Metastatic Colorectal Cancer</a></div><div class="mlt-article-authors"><!--?lit$076821981$-->T. AndrÃ© and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$076821981$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$076821981$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$076821981$-->Jan 02, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2407417?query=recirc_Semantic" target="_self">Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma</a></div><div class="mlt-article-authors"><!--?lit$076821981$-->J.D. Wolchok and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$076821981$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$076821981$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$076821981$-->Nov 07, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2402604?query=recirc_Semantic" target="_self">Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma</a></div><div class="mlt-article-authors"><!--?lit$076821981$-->C.U. Blank and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$076821981$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$076821981$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$076821981$-->May 11, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2212851?query=recirc_Semantic" target="_self">Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma</a></div><div class="mlt-article-authors"><!--?lit$076821981$-->T.K. Choueiri and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$076821981$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$076821981$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$076821981$-->Jan 02, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2411489?query=recirc_Semantic" target="_self">NEJM at ESMO â Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma</a></div><div class="mlt-article-authors"><!--?lit$076821981$-->E.J. Rubin, O.O. Yeku, and S. Morrissey</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2111380?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2111380" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2111380.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2111380"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2108330" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMra2111003" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Fever of Unknown Origin</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f0" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2111380_f0.jpg"><img src="/cms/10.1056/NEJMoa2111380/asset/8c19b16a-fc05-4e40-beb9-732de1ccb47c/assets/images/large/nejmoa2111380_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title"></div><div class="fv__item__description"><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2111380_f1.jpg"><img src="/cms/10.1056/NEJMoa2111380/asset/b46d9399-dbd4-4138-97a7-d8827026288e/assets/images/large/nejmoa2111380_f1.jpg" height="3438" width="2259" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Overall Survival and Progression-free Survival with Nivolumab plus Chemotherapy as Compared with Chemotherapy Alone.</div><div class="notes"><div role="doc-footnote">Shown are KaplanâMeier estimates of overall survival in patients with tumor-cell programmed death ligand 1 (PD-L1) expression of 1% or greater (Panel A) and in the overall population (Panel B) and KaplanâMeier estimates of progression-free survival (as assessed by blinded independent central review) in patients with tumor-cell PD-L1 expression of 1% or greater (Panel C) and in the overall population (Panel D). The P value for the analysis of progression-free survival in the overall population did not meet the prespecified boundary for significance. Symbols indicate censored data.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2111380_f2.jpg"><img src="/cms/10.1056/NEJMoa2111380/asset/2295f8d9-17e1-43cd-b70c-08421da6ab1e/assets/images/large/nejmoa2111380_f2.jpg" height="3438" width="2259" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Overall Survival and Progression-free Survival with Nivolumab plus Ipilimumab as Compared with Chemotherapy.</div><div class="notes"><div role="doc-footnote">Shown are KaplanâMeier estimates of overall survival in patients with tumor-cell PD-L1 expression of 1% or greater (Panel A) and in the overall population (Panel B) and KaplanâMeier estimates of progression-free survival (as assessed by blinded independent central review) in patients with tumor-cell PD-L1 expression of 1% or greater (Panel C) and in the overall population (Panel D). Symbols indicate censored data.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Overall Population at Baseline.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Antitumor Activity, as Assessed by Blinded Independent Central Review.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Treatment-Related Adverse Events in All the Patients Who Received Trial Treatment.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/386/5" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 386 No. 5</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Feb 03, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2108330" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">V. Makker and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Feb 03, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2112524" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Mosquito Net Use in Early Childhood and Survival to Adulthood in Tanzania</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">G. Fink and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Feb 03, 2022</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2113206" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Betibeglogene Autotemcel Gene Therapy for NonâÎ²<sup>0</sup>/Î²<sup>0</sup> Genotype Î²-Thalassemia</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">F. Locatelli and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2111380%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2111380&amp;pubId=41284186&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2111380%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2111380&amp;pubId=41284186&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright Â© 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id04158130527034978" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6bc3f84721a93-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6bc3f84721a93-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6bc3f84721a93-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6bc3f84721a93-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6bc3f84721a93-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6bc3f84721a93-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6bc3f84721a93-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6bc3f84721a93-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6bc3f84721a93-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6bc3f84721a93-SJC"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6bc3f7af01a93',t:'MTc0OTUzNjEzOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6bc3f7af01a93&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">â</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">Moreâ¦</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><paz-heuuygpgpewx></paz-heuuygpgpewx><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2111380?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=3-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><iframe name="captureIFrame_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" data-transactionid="2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" id="captureIFrame_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" target="captureIFrame_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="â" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" name="capture_screen"><input id="capture_signIn_js_version_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" name="js_version"><input id="capture_signIn_transactionId_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" data-capturefield="undefined" value="2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" type="hidden" class="capture_transactionId_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" name="capture_transactionId"><input id="capture_signIn_form_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" name="form"><input id="capture_signIn_flow_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" name="flow"><input id="capture_signIn_client_id_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" name="client_id"><input id="capture_signIn_redirect_uri_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" name="redirect_uri"><input id="capture_signIn_response_type_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" name="response_type"><input id="capture_signIn_flow_version_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" name="flow_version"><input id="capture_signIn_settings_version_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" name="settings_version"><input id="capture_signIn_locale_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" name="locale"><input id="capture_signIn_recaptcha_version_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_2k3ivajzylve2zt3pm1hpbnhxssghlt7kxy7znle" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>